4Front Ventures Corp. - Quarter Report: 2022 March (Form 10-Q)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
10-Q
(Mark One)
☒ | QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended: March 31, 2022
OR
☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission File Number
000-56075
4Front Ventures Corp.
(Exact name of registrant as specified in its charter)
83-4168417 | ||
(State or other jurisdiction of incorporation or organization) |
(IRS Employer Identification No.) |
5060 N. 40th Street
Suite 120
Phoenix, Arizona 85018
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (602)
633-3067
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class |
Trading Symbol(s) |
Name of Each Exchange on Which Registered | ||
Class A Subordinate Voting Shares, no par value |
FFNTF |
|||
FFNT |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by
Section
13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation
S-T
(Section 232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit such files). Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated
filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2
of the Exchange Act: Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
Non-accelerated filer | ☒ | Smaller reporting company | ☒ | |||
Emerging growth company | ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule
12b-2
of the Exchange Act). Yes ☐ No ☒ As of May 20, 2022, the registrant had 636,636,686 Class A subordinate voting shares outstanding.
4Front Ventures Corp.
FORM
10-Q
FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2022
TABLE OF CONTENTS
i
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements.
4FRONT VENTURES CORP.
CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS (unaudited)
As of March 31, 2022 and December 31, 2021
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
March 31, 2022 |
December 31, 2021 |
|||||||
ASSETS |
||||||||
Current assets: |
||||||||
Cash |
$ | 8,638 | $ | 22,581 | ||||
Accounts receivable, net |
2,742 | 1,946 | ||||||
Other receivables |
1,802 | 289 | ||||||
Current portion of lease receivables |
2,627 | 3,630 | ||||||
Inventory |
25,910 | 20,087 | ||||||
Current portion of notes receivable |
11 | 109 | ||||||
Prepaid expenses |
2,079 | 2,232 | ||||||
|
|
|
|
|||||
Total current assets |
43,809 | 50,874 | ||||||
|
|
|
|
|||||
Property , plant, and equipment, net |
57,815 | 42,633 | ||||||
Lease receivables |
7,543 | 6,748 | ||||||
Intangible assets, net |
43,616 | 26,246 | ||||||
Goodwill |
33,404 | 23,155 | ||||||
Right-of-use |
99,395 | 100,519 | ||||||
Deposits |
|
|
5,107 |
|
|
|
5,364 |
|
TOTAL ASSETS |
$ | 290,689 | $ | 255,539 | ||||
|
|
|
|
|||||
LIABILITIES AND SHAREHOLDERS’ EQUITY |
||||||||
LIABILITIES |
||||||||
Current liabilities: |
||||||||
Accounts payable |
$ | 5,110 | $ | 2,131 | ||||
Accrued expenses and other current liabilities |
7,596 | 9,411 | ||||||
Taxes payable |
27,619 | 23,968 | ||||||
Derivative liability |
2,202 | 3,502 | ||||||
Current portion of convertible notes |
— | 2,784 | ||||||
Current portion of lease liability |
3,700 | 3,629 | ||||||
Current portion of notes payable and accrued interest |
5,385 | 3,413 | ||||||
|
|
|
|
|||||
Total current liabilities |
51,612 | 48,838 | ||||||
|
|
|
|
|||||
Convertible notes |
14,920 | 14,641 | ||||||
Notes payable and accrued interest from related party |
48,651 | 48,266 | ||||||
Long term notes payable |
1,709 | 1,709 | ||||||
Long term accounts payable |
1,200 | 1,200 | ||||||
Contingent consideration payable |
2,393 | 2,393 | ||||||
Construction finance liability |
16,000 | — | ||||||
Deferred tax liability |
7,162 | 7,849 | ||||||
Lease liability |
93,505 | 93,111 | ||||||
|
|
|
|
|||||
TOTAL LIABILITIES |
237,152 | 218,007 | ||||||
|
|
|
|
|||||
SHAREHOLDERS’ EQUITY |
||||||||
Equity attributable to 4Front Ventures Corp. |
294,981 | 274,120 | ||||||
Additional paid-in capital |
53,235 | 52,197 | ||||||
Deficit |
(294,756 | ) | (288,857 | ) | ||||
Non-controlling interest |
77 | 72 | ||||||
|
|
|
|
|||||
TOTAL SHAREHOLDERS’ EQUITY |
53,537 | 37,532 | ||||||
|
|
|
|
|||||
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY |
$ | 290,689 | $ | 255,539 | ||||
|
|
|
|
See accompanying notes to financial statements.
1
4FRONT VENTURES CORP.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS (unaudited)
For the Three Months Ended March 31, 2022 and 2021
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
Three Months Ended March 31, |
||||||||
2022 |
2021 |
|||||||
REVENUE |
||||||||
Revenue from sale of goods |
$ | 23,083 | $ | 20,080 | ||||
Real estate income |
2,965 | 2,890 | ||||||
Total revenues |
26,048 | 22,970 | ||||||
Cost of goods sold |
(12,594 | ) | (9,125 | ) | ||||
Gross profit |
13,454 | 13,845 | ||||||
OPERATING EXPENSES |
||||||||
Selling and marketing expenses |
5,166 | 5,157 | ||||||
General and administrative expenses |
7,644 | 5,165 | ||||||
Depreciation and amortization |
847 | 774 | ||||||
Equity based compensation |
1,038 | 2,396 | ||||||
Total operating expenses |
14,695 | 13,492 | ||||||
(Loss) Income from operations |
(1,241 | ) | 353 | |||||
Other income (expense) |
||||||||
Interest income |
2 | 3 | ||||||
Interest expense |
(2,620 | ) | (2,461 | ) | ||||
Amortization of loan discount upon conversion of debt to equity |
— | (2,915 | ) | |||||
Change in fair value of derivative liability |
1,300 | (2,532 | ) | |||||
Loss on lease termination |
— | (879 | ) | |||||
Other |
103 | — | ||||||
Total other |
(1,215 | ) | (8,784 | ) | ||||
Net loss before income taxes |
(2,456 | ) | (8,431 | ) | ||||
Income tax expense |
(3,438 | ) | (2,653 | ) | ||||
Net loss from continuing operations |
(5,894 | ) | (11,084 | ) | ||||
Net loss |
(5,894 | ) | (11,084 | ) | ||||
Net income attributable to non-controlling interest |
5 | 5 | ||||||
Net loss attributable to shareholders |
$ | (5,899 | ) | $ | (11,089 | ) | ||
Basic and diluted loss per share |
$ | (0.01 | ) | $ | (0.02 | ) | ||
Weighted average number of shares outstanding, basic and diluted |
619,113,389 | 558,997,571 |
See accompanying notes to condensed financial statements.
2
4FRONT VENTURES CORP.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (unaudited)
For the Three Months Ended March 31, 2022 and 2021
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
Share Capital |
||||||||||||||||||||||||||||
Shares |
Amount |
Additional Paid-In Capital |
Deficit |
Total 4Front Ventures Corp. Shareholders’ Equity |
Non-Controlling Interest |
Total Shareholders’ Equity |
||||||||||||||||||||||
Balance, December 31, 2021 |
594,181,604 | $ | 274,120 | $ | 52,197 | $ | (288,857 | ) | $ | 37,460 | $ | 72 | $ | 37,532 | ||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Shares issued for NECC pursuant to acquisition |
28,571,428 | 17,689 | — | — | 17,689 | — | 17,689 | |||||||||||||||||||||
Share-based compensation |
— | — | 1,038 | — | 1,038 | — | 1,038 | |||||||||||||||||||||
Conversion of notes to equity |
6,235,512 | 3,122 | — | — | 3,122 | — | 3,122 | |||||||||||||||||||||
Shares issued with exercise of warrants |
88,659 | 50 | — | — | 50 | — | 50 | |||||||||||||||||||||
Net loss |
— | — | — | (5,899 | ) | (5,899 | ) | 5 | (5,894 | ) | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Balance, March 31, 2022 |
629,077,203 | $ | 294,981 | $ | 53,235 | $ | (294,756 | ) | $ | 53,460 | $ | 77 | $ | 53,537 | ||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share Capital |
||||||||||||||||||||||||||||
Shares |
Amount |
Additional Paid-In Capital |
Deficit |
Total 4Front Ventures Corp. Shareholders’ Equity |
Non-Controlling Interest |
Total Shareholders’ Equity |
||||||||||||||||||||||
Balance, December 31, 2020 |
538,851,252 | $ | 250,583 | $ | 42,116 | $ | (250,548 | ) | $ | 42,151 | $ | 52 | $ | 42,203 | ||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Shares issued for Pure Ratios earnout |
473,491 | 161 | — | — | 161 | — | 161 | |||||||||||||||||||||
Share-based compensation |
— | — | 2,396 | — | 2,396 | — | 2,396 | |||||||||||||||||||||
Conversion of notes to equity |
24,366,003 | 6,253 | — | — | 6,253 | — | 6,253 | |||||||||||||||||||||
Shares issued with exercise of stock options |
1,358,116 | 871 | — | — | 871 | — | 871 | |||||||||||||||||||||
Shares issued with exercise of warrants |
2,422,363 | 1,563 | — | — | 1,563 | — | 1,563 | |||||||||||||||||||||
Return of treasury shares |
(8,320 | ) | — | — | — | — | — | — | ||||||||||||||||||||
Net loss |
— | — | — | (11,089 | ) | (11,089 | ) | 5 | (11,084 | ) | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Balance, March 31, 2021 |
567,462,905 | 259,431 | $ | 44,512 | $ | (261,637 | ) | $ | 42,306 | $ | 57 | $ | 42,363 | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes to condensed interim financial statements.
3
4FRONT VENTURES CORP.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS (unaudited)
For the Three Months Ended March 31, 2022 and 2021
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
Three Months Ended March 31, |
||||||||
2022 |
2021 |
|||||||
CASH FLOWS FROM OPERATING ACTIVITIES |
||||||||
Net loss |
$ | (5,894 | ) | $ | (11,084 | ) | ||
Adjustments to reconcile net loss to net cash used by operating activities |
||||||||
Depreciation and amortization |
1,795 | 1,046 | ||||||
Equity based compensation |
1,038 | 2,396 | ||||||
Change in fair value of derivative liability |
(1,300 | ) | 2,532 | |||||
Accretion of lease liability |
1,513 | 612 | ||||||
Write-off of deposit |
— | 80 | ||||||
Write-off of fixed asset from terminated lease |
— | 799 | ||||||
Accretion of contingent consideration |
— | 124 | ||||||
Accretion of convertible debenture and interest |
279 | 590 | ||||||
Accrued interest on notes payable |
1,973 | 1,097 | ||||||
Interest accrued - lease receivable |
208 | — | ||||||
Deferred taxes |
(687 | ) | 632 | |||||
Amortization of loan discount upon conversion of debt to equity |
— | 2,915 | ||||||
Changes in operating assets and liabilities |
(1,293 | ) | 1,075 | |||||
NET CASH (USED IN) PROVIDED BY OPERATING ACTIVITIES |
(2,368 | ) | 2,814 | |||||
CASH FLOWS FROM INVESTING ACTIVITIES |
||||||||
Payment for NECC business combinations, net of cash acquired |
(24,998 | ) | — | |||||
Notes receivable repayments |
98 | 63 | ||||||
Sale of dispensaries and interests in cannabis licenses |
— | 1,093 | ||||||
Purchases of property and equipment |
(1,109 |
) |
(7,186 | ) | ||||
NET CASH (USED IN) INVESTING ACTIVITIES |
(26,009 |
) |
(6,030 | ) | ||||
CASH FLOWS FROM FINANCING ACTIVITIES |
||||||||
Notes payable received, net of costs |
— | 411 | ||||||
Proceeds from issuance of construction financing liability |
16,000 | — | ||||||
Proceeds from the exercise of warrants |
50 | 1,563 | ||||||
Proceeds from the exercise of stock options |
— | 871 | ||||||
Repayment of notes payable |
(1,616 | ) | (755 | ) | ||||
NET CASH PROVIDED BY FINANCING ACTIVITIES |
14,434 | 2,090 | ||||||
NET DECREASE IN CASH |
(13,943 |
) |
(1,126 | ) | ||||
CASH, BEGINNING OF QUARTER |
22,581 | 18,932 | ||||||
CASH, END OF QUARTER |
8,638 |
$ | 17,806 | |||||
See accompanying notes to condensed interim financial statements.
4
4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Three Months Ended March 31, 2022 and 2021 (unaudited)
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
Note 1: NATURE OF OPERATIONS
4Front Ventures Corp. (“4Front” or the “Company”) exists pursuant to the provisions of the British Columbia Corporations Act. On July 31, 2019, 4Front Holdings LLC (“Holdings”) completed a Reverse Takeover Transaction (“RTO”) with Cannex Capital Holdings Inc. (“Cannex”) whereby Holdings acquired Cannex and the shareholders of Holdings became the controlling shareholders of the Company. Following the RTO, the Company’s SVS are listed on the Canadian Securities Exchange (“CSE”) under the ticker “FFNT” and are quoted on the OTC (OTCQX: FFNTF).
The Company has two primary operating segments: THC Cannabis and CBD Wellness. With regard to its THC Cannabis segment, as of March 31, 2022, the Company operates six dispensaries in Massachusetts, Illinois, and Michigan, primarily under the “MISSION” brand name. As of March 31, 2022, the Company operates three production facilities in Massachusetts, Illinois and California and produces the majority of products that are sold at its own Massachusetts, Illinois, and California dispensaries. Also, as part of its THC Cannabis segment, the Company leases real estate and sells equipment, supplies and intellectual property to cannabis producers in the state of Washington.
While marijuana is legal under the laws of several U.S. states (with varying restrictions), the United States Federal Controlled Substances Act classifies all “marijuana” as a Schedule I drug, whether for medical or recreational use. Under U.S. federal law, a Schedule I drug or substance has a high potential for abuse, no accepted medical use in the United States, and a lack of safety for the use of the drug under medical supervision.
The Company’s CBD Wellness segment is focused upon its ownership and operation of its wholly owned subsidiary, Pure Ratios Holdings, Inc. (“Pure Ratios”), a
CBD-focused
wellness company in California, that sells non-THC
products throughout the United States. On January 28, 2022, the Company entered into an agreement and plan of merger (the “NECC Merger Agreement”) with New England Cannabis Corporation, Inc., a Massachusetts Corporation (“NECC”) and a wholly owned subsidiary of the Company entered into a membership interest purchase agreement (the “Everett Purchase Agreement,” and together with the NECC Merger Agreement, the “NECC Merger Agreements”) with Kenneth Stevens to purchase all of the membership interests of 29 Everett, LLC (“29 Everett”), a Massachusetts limited liability company. See Note 7 for further details on the NECC Merger Agreements and corresponding transactions under such agreements.
Management continues to evaluate the impact of the
COVID-19
pandemic on the Company’s industry and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position and results of its operations the specific impact is not readily determinable as of the date of these consolidated financial statements. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. The corporate office address of the Company is 5060 North 40th Street, Suite 120, Phoenix, Arizona, and the Company’s registered office is 550 Burrard Street, Suite 2900, Vancouver, British Columbia.
Note 2: BASIS OF PRESENTATION
The accompanying unaudited condensed consolidated interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) applicable to interim financial information and with the rules and regulations of the United States Securities and Exchange Commission (the “SEC”). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed, or omitted, pursuant to such rules and regulations.
5
4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Three Months Ended March 31, 2022 and 2021 (unaudited)
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
In the opinion of management, the unaudited interim financial statements include all adjustments necessary for the fair presentation of the results of the interim periods presented. All adjustments are of a normal recurring nature, except as otherwise noted below. These financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto for the year ended December 31, 2021, included in the Company’s Annual Report on Form
10-K,
filed April 18, 2022, with the U.S. Securities and Exchange Commission, as well as the Company’s Amendment to the Annual Report on Form 10-K,
filed April 21, 2022, and on the System for Electronic Document Analysis and Retrieval in Canada (or SEDAR). The results of operations for the interim periods are not necessarily indicative of the results of operations for any other interim period or for a full fiscal year. There have been no changes to the Company’s significant accounting policies as described in Note 2 of the Company’s 2021 Annual Report on Form
10-K.
Principles of consolidation
The accompanying condensed consolidated interim financial statements include the accounts of the Company and all entities in which the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. All intercompany accounts and transactions have been eliminated on consolidation. The financial results of NECC are included in the condensed consolidated financial statements beginning on January 28, 2022, the merger closing date.
The financial statements of the subsidiaries are prepared for the same reporting period as the parent company, using consistent accounting policies.
Note 3: SIGNIFICANT ACCOUNTING POLICIES
(a) |
Critical accounting estimates and judgments |
Our discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of the Company’s condensed consolidated interim financial statements requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, and revenue and expenses. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods. The significant judgments made by management in applying the Company’s accounting policies and the key sources of estimation uncertainty were the same as those described in the latest annual consolidated financial statements.
We cannot predict what future laws and regulations might be passed that could have a material effect on our results of operations. We assess the impact of significant changes in laws and regulations on a regular basis and update the assumptions and estimates used to prepare our financial statements when we deem it necessary.
6
4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Three Months Ended March 31, 2022 and 2021 (unaudited)
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
(b) |
Recent Accounting Pronouncements |
Recently Adopted
i. |
In December 2019, the FASB issued ASU 2019-12, “Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes”, which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ASU 2019-12 was effective for the Company beginning January 1, 2021. Adoption of this standard did not materially impact the Company’s consolidated financial position, results of operations or cash flows. |
ii. |
In August 2020, the FASB issued ASU 2020-06, “Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40)”. ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. Adoption of this standard did not materially impact the Company’s consolidated financial position, results of operations or cash flows. |
iii. |
In May 2021, the FASB issued ASU 2021-04, “Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (Subtopic 815-40)”. ASU 2021-04 clarifies and reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 is effective for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. Adoption of this standard did not materially impact the Company’s consolidated financial position, results of operations or cash flows. |
Accounting Pronouncements Not Yet Adopted
i. |
In October 2021, the FASB issued ASU 2021-08, “Business Combinations - Accounting for Contract Assets and Contract Liabilities (Topic 805)”. The amendments in this update address diversity and inconsistency related to the recognition and measurement of contract assets and contract liabilities acquired in a business combination by requiring that an acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606, Revenue from Contracts with Customers. ASU 2021-08 is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. The Company does not expect the adoption of this ASU to have a material impact on the Company’s financial statements. |
Note 4: INVENTORY
The Company’s inventories include the following as of March 31,
2022
and December 31, 2021: 7
4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Three Months Ended March 31, 2022 and 2021 (unaudited)
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
March 31, 2022 |
December 31, 2021 |
|||||||
Raw Materials - unharvested cannabis |
$ | 4,409 | $ | 2,164 | ||||
Raw materials CBD and ingredients |
37 | 36 | ||||||
Work in process - flower and extract |
11,325 | 7,780 | ||||||
Finished goods - cultivation supplies |
2,351 | 1,734 | ||||||
Finished goods - packaged products |
7,788 | 8,373 | ||||||
|
|
|
|
|||||
Total |
$ | 25,910 | $ | 20,087 | ||||
|
|
|
|
Note 5: PROPERTY, PLANT, AND EQUIPMENT
Property, plant and equipment and related depreciation are summarized in the table below:
March 31, 2022 |
December 31, 2021 |
|||||||
Land |
$ |
774 |
$ |
— |
||||
Buildings & improvements |
13,509 |
1,483 |
||||||
Construction in process |
218 |
63 |
||||||
Furniture, equipment & other |
16,841 |
13,425 |
||||||
Leasehold improvements |
35,514 |
35,538 |
||||||
|
|
|
|
|||||
Total |
$ |
66,856 |
$ |
50,509 |
||||
Less: accumulated depreciation |
(9,041 |
) |
(7,876 |
) | ||||
|
|
|
|
|||||
Total property, plant, and equipment, net |
$ |
57,815 |
$ |
42,633 |
||||
|
|
|
|
|
|
|
|
|
On January 28, 2022, in conjunction with a business combination with NECC, the Company acquired property, plant, and equipment totaling $15,238 (Note 7). The Company subsequently sold the property, plant, and equipment to a third-party and leased back the equipment from the third-party. As discussed in Note 9, the Company recognized this fact pattern as a failed sale-leaseback transaction, whereby the Company recognized the fixed assets on the balance sheet of NECC and established a construction finance liability for rental payments made as part of the lease agreement.
Approximately $33,000 of property and equipment is secured by LI Lending as collateral on the LI Lending note (Note 9). There were no significant contractual commitments for future capital expenditures as of March 31, 2022 and December 31, 2021.
Depreciation of property, plant and equipment is computed using the straight-line method over the asset’s estimated useful life. The Company does not depreciate land, which has an indefinite useful life. Depreciation
expense for the for the three months ended March 31, 2022 and 2021 was $1,165 and $463, respectively, of which $948 and $325, respectively, is included in cost of goods sold. Note 6: INTANGIBLE ASSETS AND GOODWILL
Intangible Assets
Intangible assets are recorded at cost less accumulated amortization and impairment losses. Intangible assets acquired in a business combination are measured at fair value at the acquisition date. Amortization of definite life intangibles is recognized on a straight-line basis over their estimated useful lives. The estimated useful lives, residual values, and amortization methods are reviewed at each year end, and any changes in estimates are accounted for prospectively.
Intangible assets and related amortization are summarized in the table below:
Licenses |
Customer Relationships |
Non-Competition Agreements |
Know-How |
Total |
||||||||||||||||
Balance, December 31, 2020 |
$ | 20,146 | $ | 1,668 | $ | 43 | $ | 6,933 | $ | 28,790 | ||||||||||
Amortization expense |
— | (580 | ) | (43 | ) | (1,921 | ) | (2,544 | ) | |||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Balance, December 31, 2021 |
$ | 20,146 | $ | 1,088 | $ | — | $ | 5,012 | $ | 26,246 | ||||||||||
NECC merger and 29 Everett acquisition (Note 7) |
18,000 | — | — | — | 18,000 | |||||||||||||||
Amortization expense |
— | (145 | ) | (485 | ) | (630 | ) | |||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Balance, March 31, 2022 |
$ | 38,146 | $ | 943 | $ | — | $ | 4,527 | $ | 43,616 | ||||||||||
|
|
|
|
|
|
|
|
|
|
Goodwill
Balance, December 31, 2020 |
$ |
23,155 |
||
|
|
|||
Balance, December 31, 2021 |
$ |
23,155 |
||
NECC merger and 29 Everett acquisition (Note 7) |
10,249 | |||
|
|
|||
Balance, March 31, 2022 |
$ |
33,404 |
||
|
|
Impairment of Intangible Assets and Goodwill
On an annual basis, the Company assesses the Company’s reporting units (“RUs”) for indicators of impairment or when facts or circumstances suggest that it is more likely than not that the carrying amount may exceed fair value. For the purpose of impairment testing, goodwill is allocated to the Company’s RUs to which it relates.
Goodwill was not tested for impairment during the three months ended March 31, 2022.
8
4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Three Months Ended March 31, 2022 and 2021 (unaudited)
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
Three Months Ended March 31, 2021
On January 28, 2022, the Company entered into the NECC Merger Agreements with NECC and 29 Everett for total consideration of
$44,689. As part of the purchase price allocation of the acquisition and merger, the Company recognized $18,000 of acquired licenses and $10,249
of goodwill based on the consideration transferred and fair value of assets acquired. For further details on the acquisition and purchase price allocation, see Note 7.
Year Ended December 31, 2021
In 2021, management assessed indicators of impairment and concluded the below for the respective RUs:
Retail, Production and Ancillary Cannabis Reporting Units
Management did not identify any significant negative triggering events that would suggest it is more likely than not that impairment exists. Therefore, further analysis is not required for these RUs.
Pure Ratios RU
As of March 31, 2022 and December 31, 2021, the accumulated impairment is $13,400, which is due to goodwill impairment of the entire outstanding balance of goodwill on the Pure Ratios segment for the year ended December 31, 2020. As a result, the segment does not have a balance of goodwill or intangible assets remaining as of December 31, 2021.
Note 7: ACQUISITIONS AND BUSINESS COMBINATIONS
On January 28, 2022, the Company entered into the merger agreement (the “NECC Merger”) with NECC, Kenneth V. Stevens (“Mr. Stevens”), who is the sole owner of all of the issued and outstanding capital stock of NECC, and 4Front NECC Acquisition Co., a Massachusetts corporation (the “NECC Merger Sub”). At the effective time of the merger, the Company (i) paid Mr. Stevens cash in the amount of
$9,000,000, and (ii) issued Mr. Stevens 28,571,428 Class A Subordinate Voting shares of the Company (the “SVS”).
In connection with the consummation of the NECC Merger on January 28, 2022, Mission Partners RE, LLC, a Delaware limited liability company wholly owned by the Company (“Mission Partners RE”), and Mr. Stevens entered into the first amendment to that certain membership interest purchase agreement (the “Everett Purchase Agreement”). Pursuant to the Everett Purchase Agreement, the Company (through Mission Partners RE) completed its acquisition
six-month
anniversary of January 28, 2022. The Merger and Purchase Agreement were recorded as one transaction (collectively, referred to as the “NECC Acquisitions”), as the entities were commonly owned by the same individual and the purchase of Everett LLC was contingent on the Merger with NECC.
The NECC Merger was accounted for as a business combination in accordance with ASC 805. The Company has determined preliminary fair values of the assets acquired and liabilities assumed in the NECC Merger. These values are subject to change as the Company completes its determination of the fair value of assets acquired and liabilities assumed. Upon acquisition of NECC and Everett LLC on January 28, 2022, the Company consolidated the operations of Everett LLC into NECC.
The Company entered into the NECC Merger in order to acquire cannabis licenses, as well as property and equipment held by NECC to increase the Company’s presence in Massachusetts and the northeastern United States. As part of the NECC Merger, the Company incurred $596,000 in transaction costs, which were expensed as incurred.
9
4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Three Months Ended March 31, 2022 and 2021 (unaudited)
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
The following tables presents the preliminary purchase price allocation for the NECC Merger:
Cash consideration |
$ | 25,000 | ||
Seller note |
2,000 | |||
Equity consideration - common stock |
17,689 | |||
|
|
|||
Total Purchase Price |
$ | 44,689 | ||
|
|
Description |
Fair value |
|||
Assets acquired: |
||||
Cash |
$ | 2 | ||
Inventory |
|
|
2,000 |
|
Property , plant, and equipment |
15,238 | |||
Intangible asset - licenses |
18,000 | |||
|
|
|||
Total assets acquired |
$ | 35,240 | ||
|
|
|||
Liabilities assumed: |
||||
Accounts payable |
800 | |||
|
|
|||
Total liabilities assumed |
$ | 800 | ||
|
|
|||
Estimated fair value of net assets acquired |
$ | 34,440 | ||
|
|
|||
Estimated Goodwill |
$ | 10,249 | ||
|
|
Goodwill and Intangible Assets
Goodwill is represented by the future potential for the generation of positive cash flows and future relationships associated with the Company’s operations. While NECC had yet to generate revenues as of the date of the Merger, the Company identified that the inputs of the business were in place to begin generating revenue during fiscal year 2022. The Company adjusts provisional goodwill balance when new information is obtained regarding the valuation of acquired assets and liabilities during a one-year measurement period from the date of acquisition in accordance with ASC 805-10. The Company has determined that the goodwill recognized in the above acquisition is not deductible for tax purposes.
The intangible assets acquired by the Company consist of cannabis licenses for operations. Utilizing alike licenses as a benchmark, the Company determined that the licenses acquired are indefinite lived assets.
Unaudited Pro Forma Results
The following unaudited pro forma financial information presents the results of operations of the Company and NECC for the three months ended March 31, 2022 and 2021, as if the acquisition had occurred as of the beginning of the first period presented instead of on January 28, 2022. The pro forma information does not necessarily reflect the results of operations that would have occurred had the entities been a single company during those periods.
The unaudited pro forma financial information for the Company and NECC is as follows:
For the For the Three Months Ended March 31, |
||||||||||||||||
2022 |
2021 |
|||||||||||||||
Reported |
Proforma |
Reported |
Proforma |
|||||||||||||
Revenues |
$ | 26,048 | $ | 26,048 | $ | 22,970 | $ | 22,970 | ||||||||
(Loss) income from operations |
(1,241 | ) | (1,241 | ) | 353 | 344 | ||||||||||
|
|
|
|
|
|
|
|
|||||||||
Net loss |
$ | (5,894 | ) | $ | (5,609 | ) | $ | (11,084 | ) | $ | (11,093 | ) | ||||
|
|
|
|
|
|
|
|
|||||||||
Basic and diluted earning (loss) per share |
$ | (0.01 | ) | $ | (0.02 | ) | $ | (0.02 | ) | $ | (0.02 | ) |
10
4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Three Months Ended March 31, 2022 and 2021 (unaudited)
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
Note 8: LEASES
The Company has operating leases for its facilities where the Company conducts its operations. These leases have remaining lease terms ranging from 1.25 year
s
to 19.43 years. All real estate leases are recorded on the balance sheet. Equipment and other assets and operating lease liabilities. Certain real estate leases require payment for taxes, insurance and maintenance which are considered
non-real
estate leases with an initial term of twelve months or less are not recorded on the balance sheet. Lease agreements for some locations provide for rent escalations and renewal options. Many leases include one or more options to renew the lease at the end of the initial term. The Company considered renewals in its right-of-use
non-lease
components. The Company accounts for real estate leases and the related fixed non-lease
components together as a single component. The Company determines if an arrangement is a lease at inception. The Company must consider whether the contract conveys the right to control the use of an identified asset. Certain arrangements require significant judgment to determine if an asset is specified in the contract and if the Company directs how and for what purpose the asset is used during the term of the contract.
There are no material residual guarantees associated with any of the Company’s leases, and there are no significant restrictions or covenants included in the Company’s lease agreements. Certain leases include variable payments related to common area maintenance and property taxes, which are billed by the landlord, as is customary with these types of charges for office space.
The Company’s lease agreements occasionally provide an implicit borrowing rate. When implicit borrowing rates are provided, the Company utilizes these implicit borrowing rates to calculate assets and liabilities at the end of each reporting period. The Company may enter into leases that do not provide an implicit borrowing rate. When an implicit borrowing rate is not provided, the Company uses a benchmark approach to derive an appropriate imputed discount rate. The Company will benchmark itself against other companies of similar credit ratings and comparable quality and derive an imputed rate, which was used in a portfolio approach to discount its lease liabilities.
right-of-use
For the three months ended March 31, 2022 and 2021 the Company recorded $4,822 and $4,872 in operating lease expense
,
respectively. (a) |
The Company as a Lessee |
The following table summarizes the Company’s operating leases:
Classification - Consolidated Balance Sheet |
March 31, 2022 |
December 31, 2021 |
||||||||
Assets |
||||||||||
Operating lease assets |
Operating Lease Assets |
$ | 99,395 | $ | 100,519 | |||||
Liabilities |
||||||||||
Current |
||||||||||
Operating |
Current portion of operating lease liabilities |
3,700 | 3,629 | |||||||
Noncurrent |
||||||||||
Operating |
Operating lease liabilities |
93,505 | 93,111 | |||||||
|
|
|
|
|||||||
Total lease liabilities |
$ | 97,205 | $ | 96,740 | ||||||
|
|
|
|
11
4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Three Months Ended March 31, 2022 and 2021 (unaudited)
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
The components of lease expense are included in cost of goods sold, general and administrative expenses, and selling and marketing expenses, based on the underlying use of the right-of-use asset.
Maturities of lease liabilities for third-party operating leases as of March 31, 2022 were as follows:
Three months ending March 31, 2022 |
Operating Leases |
|||
2022 |
$ | 11,091 | ||
2023 |
15,433 | |||
2024 |
15,859 | |||
2025 |
16,213 | |||
2026 |
16,594 | |||
2027 |
16,603 | |||
2028 and Thereafter |
227,684 | |||
|
|
|||
Total undiscounted cash flows |
$ | 319,477 | ||
Less discounting |
(222,272 | ) | ||
|
|
|||
Total lease payments |
$ | 97,205 | ||
|
|
The Company has assets and lease liabilities for leased real estate for dispensaries, cultivation and production facilities and office space. The incremental borrowing rate used for leases for 2022 was 10.25 - 18% and was 10.25 - 18% for 2021.
right-of-use
(b) |
The Company as a Lessor: |
The Company leases a building in Elma, Washington that is subleased by the Company to a third party. This sublease is classified as a finance lease with a long term lease receivable balance of $7,543 and a short term lease receivable balance of $2,627 as of March 31, 2022 compared to a long term lease receivable balance of $6,748 and a short term lease receivable balance of $3,630 as of December 31, 2021. This lease generated $692 of the $2,965 and $791 of the $2,890
in real estate income for the three months ended March 31, 2022 and 2021, respectively.
The Company owned buildings in Olympia, Washington that were leased to a third party. This lease was classified as a finance lease. On December 17, 2020, the Company sold the Olympia building and other assets as part of a sale and leaseback transaction and this lease was cancelled. The Company applied ASC 842 to a new sublease to the same third party and classified the new sublease as an operating lease. The lease receivable was sold to the purchaser of the assets as part of the sale and leaseback transaction. This lease generated $2,273 of the $2,965 and $2,099 of the $2,890
The following table summarizes changes in the Company’s
lease
receivables: 12
4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Three Months Ended March 31, 2022 and 2021 (unaudited)
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
March 31, 2022 |
December 31, 2021 |
|||||||
Balance, beginning of the year |
$ | 10,378 | $ | 11,045 | ||||
Interest |
692 | 2,783 | ||||||
Lease payments received |
(900 | ) | (3,450 | ) | ||||
|
|
|
|
|||||
Balance, end of the period |
$ | 10,170 | $ | 10,378 | ||||
Less current portion |
(2,627 | ) | (3,630 | ) | ||||
|
|
|
|
|||||
Long-term lease receivables |
$ | 7,543 | $ | 6,748 | ||||
|
|
|
|
Future minimum lease payments receivable (principal and interest) on the leases are as follows:
Operating Leases |
||||
2022 |
$ | 2,730 | ||
2023 |
1,575 | |||
2024 |
— | |||
2025 |
— | |||
Thereafter |
— | |||
|
|
|||
Total minimum lease payments |
4,305 | |||
Effect of discounting |
(667 | ) | ||
Present value of minimum lease payments |
3,638 | |||
Present value of residual value of leased property |
6,532 | |||
|
|
|||
Total lease receivable |
10,170 | |||
Current portion lease receivable |
(2,627 | ) | ||
|
|
|||
Long-term lease receivable |
$ | 7,543 | ||
|
|
13
4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Three Months Ended March 31, 2022 and 2021 (unaudited)
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
Note 9: NOTES PAYABLE AND CONVERTIBLE NOTES
The Company’s notes payable and convertible notes are as follows:
LI Lending, LLC |
May 2020 Convertible Notes |
May 2020 Convertible Notes (Swap) |
October 2021 Convertible Note |
Other Loans |
Total |
|||||||||||||||||||
Balance, December 31, 2020 |
$ | 45,362 | $ | 2,855 | $ | 11,867 | $ | — | $ | 6,931 | $ | 67,015 | ||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Loans advanced, net |
— | — | — | 14,376 | 930 | 15,306 | ||||||||||||||||||
Loan payments |
(4,671 | ) | — | — | — | (1,079 | ) | (5,750 | ) | |||||||||||||||
Converted to equity |
— | (5,852 | ) | (11,867 | ) | — | — | (17,719 | ) | |||||||||||||||
Accrued interest |
7,575 | 2,997 | — | 265 | 1,124 | 11,961 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Balance, December 31, 2021 |
$ | 48,266 | $ | — | $ | — | $ | 14,641 | $ | 7,906 | $ | 70,813 | ||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Loans advanced, net |
— | — | — | — | 2,000 | 2,000 | ||||||||||||||||||
Loan payments |
(1,506 | ) | — | — | — | (110 | ) | (1,616 | ) | |||||||||||||||
Converted to equity |
— | — | — | — | (2,784 | ) | (2,784 | ) | ||||||||||||||||
Accrued interest |
1,891 | — | — | 279 | 82 | 2,252 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Balance, March 31, 2022 |
$ | 48,651 | $ | — | $ | — | $ | 14,920 | $ | 7,094 | $ | 70,665 | ||||||||||||
Less current portion |
— | — | — | — | (5,385 | ) | (5,385 | ) | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Long-term portion |
$ | 48,651 | $ | — | $ | — | $ | 14,920 | $ | 1,709 | $ | 65,280 | ||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Notes
On May 14, 2020, the Company issued $5,827 in convertible notes to existing investors in the Company. The notes pay interest of 5% per annum and have a maturity date of February 28, 2022.
$0.25 per share at any time at the option of the holder. The Company can require mandatory conversion at any time that the Company’s stock price remains above $0.50 for 45 consecutive days. In 2021, the Company enacted the mandatory conversion feature and converted the May 2020 Convertible Note balance to subordinate voting shares.
As part of issuing the convertible notes, the investors were given the right to exchange stock in the Company into separate convertible notes (swap notes). In total 29,448,468 shares with a value of $13,661 were exchanged for $13,661 in convertible notes. These notes were effective May 28, 2020, have a maturity date of May 28, 2025, and can be converted into Class A Subordinate Voting Shares of the Company for $0.46 per share at any time at the option of the holder. The notes pay no interest if the Company’s annual revenue is greater than $15,000, and 3% annually otherwise. The Company can require mandatory conversion at any time that the Company’s stock price remains above $0.92 for 45 consecutive days. In 2021, the Company exercised the mandatory conversion feature and converted the May 2020 Convertible Note (Swap) balance to subordinate voting shares.
On October 6, 2021, the Company entered into a convertible promissory note purchase agreement for $15,000, less issuance costs of $624, resulting in net proceeds of $14,376. The notes pay interest of 6% per annum and have a maturity date of October 6, 2024. The
$1.03 per share at any time at the option of the holder. As of March 31, 2022, no payments have been made for this loan.
LI Lending LLC
On May 10, 2019, the Company entered into a loan agreement with LI Lending LLC, a related party, for $50,000. LI Lending LLC is related because an officer of the Company is a part-owner of LI Lending LLC. As of March 31, 2022, the Company had drawn $45,000 on the loan in two amounts, an initial $35,000 and a final $10,000, both bearing a 10.25% and 12.25% interest rate, respectively. The outstanding balance as of March 31, 2022 is $49,027, less debt discount of $376, for a net balance of $48,651. See Note 1
3
for further discussion of this related party transaction. In April 2020, the loan was amended. In exchange for consent to allow the sale of the Pennsylvania and Maryland assets and the release of related collateral, the Company agreed to make prepayments of principal to LI Lending LLC in the amount of
$250 per month for an eight-month period beginning on May 1, 2020. The $2,000 prepayment was applied to the initial $35,000 amount
,
decreasing the balance to $33,000. Additionally, the Company agreed to pay an increased interest rate of 12.25% on the final $10,000 of the loan until such time as this amount has been paid down,
with the initial $33,000 amount continuing to be subject to the original 10.25% interest rate. 14
4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Three Months Ended March 31, 2022 and 2021 (unaudited)
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
In December 2020, the loan was amended to allow for the release of collateral for the sale and leaseback transactions described in Note 8 above, which was entered into with Innovative Industrial Properties, Inc. (“IIPR”). The amendment increased both interest rates
by 2.5% on the loan amounts but allowed the payments resulting from the incremental interest to be deferred until January 1, 2022. The Company elected to defer payment, and the additional 2.5% interest is accrued each month and added to the balance of the loan. The Company was required to make interest-only payments monthly of 10.25% on the initial $33,000 and 12.25% on the final $10,000 of the loan until January 1, 2022 when the interest rates of 12.75% for the initial $33,000 and 14.75% for the final $10,000 took effect for the remaining term.
The loan matures on May 10, 2024. An exit fee of 20% of the principal balance will be due as principal is repaid. Accrued interest expense of $1,891 includes a loan discount accretion expense of $125
Other
Outstanding as of March 31,
2022
were other payables totaling $7,094 which include notes issued as part of the acquisitions of Healthy Pharms, NECC, and Arkansas entities as follows:
Other
Subsidiary |
Terms |
March 31, 2022 |
December 31, 2021 |
|||||||
Healthy Pharms Inc. |
Unsecured convertible note, due November 18, 2021 at 12% per annum | $ | — | $ | 2,784 | |||||
Healthy Pharms Inc. |
Unsecured promissory note at $0.50 per share due December 18, 2022 at 10% per annum (1) | 3,294 | 3,213 | |||||||
NECC |
Promissory note due July 28, 2022 at 10% per annum | 2,000 | — | |||||||
Arkansas Entities |
Unsecured Promissory note, monthly interest payments at 14% per annum | 1,709 | 1,709 | |||||||
Equipment Loans |
Secured by equipment, monthly payments beginning in 2021 at 15% per annum | — | 49 | |||||||
Other |
Various | 91 | 151 | |||||||
Total Notes Payable and Convertible Notes |
$ | 7,094 | $ | 7,906 | ||||||
1
(1) | In November 2021 , the unsecured promissory note was modified to be due and payable in full on or before December 18, 2022. The Company concluded the extension resulted in a debt modification under ASC 470 |
Future minimum payments on the notes payable and convertible debt are as follows:
15
4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Three Months Ended March 31, 2022 and 2021 (unaudited)
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
March 31, 2022 |
||||
2022 |
$ | 6,935 | ||
2023 |
143 | |||
2024 |
65,280 | |||
2025 |
— | |||
2026 |
— | |||
Thereafter |
— | |||
Total minimum payments |
72,358 | |||
Effect of discounting |
(1,693 | ) | ||
Present value of minimum payments |
70,665 | |||
Less current portion |
(5,385 | ) | ||
Long-term portion |
$ | 65,280 | ||
Construction Finance Liability
On January 28, 2022, a wholly owned subsidiary of the Company acquired property at 29 Everett in conjunction with the NECC Merger (see Note 7 for further details on the transaction). Concurrently, effective January 28, 2022, the Company sold a portion of the property it had acquired in the acquisition for
$16,000
, less security deposits withheld of $403, which was the cost to the Company. In connection with the sale of the property at 29 Everett, the Company agreed to lease the location back for cultivation, effective on January 28, 2022. The details of the lease included three purchase options that the Company can exercise, in which the Company has the ability to repurchase the property on either the second, fourth, or sixth anniversary of the lease agreement. As the Company plans to exercise one of the three purchase options available, per guidance prescribed in ASC 842, this transaction was determined to be a finance lease. Under this guidance, lease arrangements where assets are sold and leased back, whereby the agreement is classified as a finance lease, does not meet the definition of a sale because control is never transferred to the buyer-lessor. As a result, the transaction was treated as a failed sale-leaseback financing arrangement. On January 28, 2022, the Company recorded a construction finance liability for the proceeds received from the sale to recognize a liability resulting from the failed sale-leaseback transaction.
The initial term of the agreement is 20 years, with two options to extend the term for five years each. The
initial monthly rent payment is equal to
$140 for the first year of the agreement, with 3% annual increases over the life of the agreement. As of March 31, 2022, the total finance liability associated with this transaction is
$16,000
.
16
4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Three Months Ended March 31, 2022 and 2021 (unaudited)
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
Note 10: SHARE CAPITAL AND EQUITY
The Company has authorized an unlimited number of Class A Subordinate Voting Shares (“SVS”) and Class C Multiple Voting Shares (“MVS”), all with no par value. In December 2020, the shareholders of the Company passed a resolution to permit the Company to convert all Class B Subordinate Voting Shares (“PVS”) shares into Class A shares and cancel the Class B PVS equity class, which occurred in 2020.
All share classes are included within share capital in the consolidated statements of stockholders’ equity on an as-converted basis. Each share class is entitled to notice of and to attend at any meeting of the shareholders, except a meeting of which only holders of another particular class of shares will have the right to vote. All share classes are entitled to receive dividends, as and when declared by the Company, on an
as-converted
basis, and no dividends will be declared by the Company on any individual class unless the Company simultaneously declares or pays dividends on all share classes. No subdivision or consolidation of any share class shall be made without simultaneously subdividing or consolidating all share classes in the same manner. Voting shares activity for the periods presented is summarized as follows:
Class A Subordinate Voting Shares |
Class C Multiple Voting Shares |
Total |
||||||||||
Balance, December 31, 2020 |
537,575,044 | 1,276,208 | 538,851,252 | |||||||||
|
|
|
|
|
|
|||||||
Share capital issuances |
55,330,352 | — | 55,330,352 | |||||||||
|
|
|
|
|
|
|||||||
Balance, December 31, 2021 |
592,905,396 | 1,276,208 | 594,181,604 | |||||||||
|
|
|
|
|
|
|||||||
Share capital issuances |
34,895,599 | — | 34,895,599 | |||||||||
|
|
|
|
|
|
|||||||
Balance, March 31, 2022 |
627,800,995 | 1,276,208 | 629,077,203 | |||||||||
|
|
|
|
|
|
Class A Subordinate Voting Shares
Holders of Class A Subordinate Voting Shares are entitled to one vote in respect of each SVS.
Class C Multiple Voting Shares
Holders of Class C Multiple Voting Shares are entitled to 800 votes in respect of each MVS. One MVS can convert to one SVS but are not convertible until the later of the date that (i) the aggregate number of PVS and MVS held by the Initial Holders (being the MVS holders on their initial issuance) are reduced to a number which is less than 50% of the aggregate number of PVS and MVS held by the Initial Holders on the date of completion of the Business Combination with Cannex, and (ii) 3 years following the date of the business combination with Cannex.
Series |
Shares outstanding as of March 31, 2022 |
As converted to SVS Shares |
||||||
Class A – Subordinate Voting Shares |
627,800,995 | 627,800,995 | ||||||
Class C – Multiple Voting Shares |
1,276,208 | 1,276,208 | ||||||
|
|
|
|
|||||
629,077,203 | 629,077,203 | |||||||
|
|
|
|
17
4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Three Months Ended March 31, 2022 and 2021 (unaudited)
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
On November 23, 2020, the Company closed a brokered private placement and issued 24,644,500 Units at a price of C$0.70 per Unit. Each Unit is comprised of one subordinate voting share of the Company and
one-half
of a subordinate voting share purchase warrant. Each whole warrant entitles the holder to purchase one subordinate voting share for a period of two years from the date of issuance at an exercise price of C$0.90 per subordinate voting share. Net proceeds from this transaction were $11,557 net of share issuance costs of $690. Because of the Canadian dollar denominated exercise price, these warrants do not qualify to be classified within equity and are therefore classified as derivative liabilities at fair value with changes being reported through the statement of operations. On November 23, 2020, the warrants were valued using the Black Scholes option pricing model at $4,229 using the following assumptions: Share Price: C$0.94; Exercise Price: C$0.90; Expected Life: 2 years; Annualized Volatility: 87.73%; Dividend yield: 0.00%; Discount Rate: 0.16%; C$ Exchange Rate:1.31.
On March 31, 2022, the warrants were revalued using the Black Scholes option pricing model, using the following assumptions: Share Price: C$1.00; Expected Life: 0.65 years; Annualized Volatility: 70.96%; Dividend yield: 0%; Discount Rate: 1.06%; C$ Exchange Rate: 1.28. The decrease in the value of the derivative liability of $1,300 is reflected in the statement of operations as a $1,300 gain on the change in fair value of the derivative liability.
Note 11: WARRANTS
As of March 31, 2022, there were share purchase warrants outstanding to purchase up to 26,103,578 SVS shares:
Series |
Number of warrants |
Weight-average exercise price |
||||||
Balance, December 31, 2021 |
26,192,237 | $ | 0.75 | |||||
Issued |
— | — | ||||||
Exercised |
(88,659 | ) | 0.56 | |||||
|
|
|
|
|||||
Balance, March 31, 2022 |
26,103,578 | $ | 0.75 | |||||
|
|
|
|
As of March 31, 2022, the Company has the following warrants outstanding and exercisable:
Warrants Outstanding |
Exercise Price |
Expiry Date | |||||||||||
10,403,150 | C$ | 0.90 | November 23, 2022 | ||||||||||
209,426 | C$ | 0.70 | November 23, 2022 | ||||||||||
12,135,922 | 0.82 | December 17, 2022 | |||||||||||
2,230,080 | 0.67 | January 29, 2023 | |||||||||||
625,000 | C$ | 0.80 | October 6, 2024 | ||||||||||
500,000 | C$ | 0.80 | October 6, 2025 | ||||||||||
|
|
||||||||||||
26,103,578 | |||||||||||||
|
|
Note 12: SHARE-BASED COMPENSATION
The Company adopted two equity incentive plans where the Company may grant Class A stock options. Under the terms of the plans, the maximum number of stock options which may be granted are a total of 10% of the number of shares outstanding assuming conversion of all shares to SVS. The exercise price for stock options issued under the plans will be set by the compensation committee of the board of directors but will not be less than 100% of the fair market value of the Company’s shares on the grant date. Stock options have a maximum term of 10 years from the date of grant. Stock options vest at the discretion of the Board.
18
4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Three Months Ended March 31, 2022 and 2021 (unaudited)
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
As of March 31, 2022, the Company had the following options outstanding and exercisable on an
as-converted
basis: Grant Date |
Strike Price in CAD$ |
Outstanding Options |
Exercisable Options |
Life Remaining (years) |
||||||||||||
July 31, 2019 |
0.10 | 6,245,840 | 6,245,840 | 2.47 | ||||||||||||
July 31, 2019 |
1.00 | 7,783,332 | 7,783,332 | 0.70 | ||||||||||||
July 31, 2019 |
1.00 | 1,166,667 | 1,166,667 | 1.52 | ||||||||||||
July 31, 2019 |
1.50 | 508,333 | 508,333 | 2.20 | ||||||||||||
July 31, 2019 |
1.50 | 800,000 | 800,000 | 2.21 | ||||||||||||
August 22, 2019 |
0.80 | 5,237,720 | 4,126,609 | 2.40 | ||||||||||||
August 22, 2019 |
1.00 | 6,150,000 | 4,894,444 | 2.40 | ||||||||||||
November 1, 2019 |
0.80 | 1,200,000 | 900,000 | 2.59 | ||||||||||||
February 3, 2020 |
0.80 | 375,000 | 145,833 | 2.85 | ||||||||||||
June 8, 2020 |
0.80 | 25,000 | 10,417 | 3.19 | ||||||||||||
July 31, 2020 |
0.80 | 1,200,000 | 1,141,667 | 3.34 | ||||||||||||
September 15, 2020 |
0.86 | 7,315,860 | 7,315,860 | 3.46 | ||||||||||||
October 2, 2020 |
0.77 | 3,000,000 | 3,000,000 | 3.51 | ||||||||||||
November 24, 2020 |
0.94 | 1,675,000 | 1,675,000 | 3.65 | ||||||||||||
December 2, 2020 |
1.11 | 2,900,000 | 2,900,000 | 3.68 | ||||||||||||
December 21, 2020 |
1.06 | 1,200,000 | 500,000 | 3.73 | ||||||||||||
March 18, 2021 |
1.63 | 6,650,000 | 3,325,000 | 3.97 | ||||||||||||
April 2, 2021 |
1.36 | 200,000 | 133,333 | 4.01 | ||||||||||||
April 21, 2021 |
1.58 | 175,000 | 116,667 | 4.06 | ||||||||||||
June 23, 2021 |
1.56 | 450,000 | 300,000 | 4.23 | ||||||||||||
November 11, 2021 |
1.33 | 25,000 | 6,250 | 4.62 | ||||||||||||
January 25, 2022 |
0.89 | 1,100,000 | 99,306 | 4.82 | ||||||||||||
February 1, 2022 |
0.84 | 100,000 | 8,056 | 4.84 | ||||||||||||
February 17, 2022 |
0.85 | 100,000 | 5,833 | 4.89 | ||||||||||||
March 1, 2022 |
1.09 | 200,000 | 8,333 | 4.92 | ||||||||||||
55,782,752 | 47,116,780 | 2.79 |
Stock option activity is summarized as follows:
19
4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Three Months Ended March 31, 2022 and 2021 (unaudited)
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
Number of Options |
Weighted Average Price CAD$ |
Weighted Average Years |
||||||||||
Balance December 31, 2020 |
50,427,065 | 0.84 | 3.72 | |||||||||
Granted |
7,900,000 | 1.62 | 5.00 | |||||||||
Exercised |
(2,737,326 | ) | 1.04 | — | ||||||||
Forfeited/ Expired |
(1,306,987 | ) | 0.43 | — | ||||||||
Balance December 31, 2021 |
54,282,752 | 0.94 | 2.97 | |||||||||
Granted |
1,500,000 | 0.91 | 5.00 | |||||||||
Exercised |
— | — | — | |||||||||
Forfeited/ Expired |
— | — | — | |||||||||
Balance March 31, 2022 |
55,782,752 | 0.94 | 2.79 |
During the three months ended March 31, 2022 and 2021, the Company recognized share-based compensation of $1,038 and $2,396
,
respectively. In determining the amount of equity-based compensation during the year, the Company used the Black-Scholes option pricing model to establish fair value of options granted during the year with the following key assumptions:
2022 |
2021 |
|||||||
Risk-Free Interest Rate |
2.42 | % | 0.87 | % | ||||
Expected Life (years) |
5.00 | 5.00 | ||||||
Expected Annualized Volatility |
71.30 | % | 86.20 | % | ||||
Expected Dividend Yield |
— | — |
Note 13: RELATED PARTIES
Related party transactions
LI Lending LLC
Linchpin Investors LLC (“Linchpin”), a subsidiary of the Company, and LI Lending LLC (“LI Lending”) entered into a Construction Loan Agreement dated May 10, 2019, as amended, whereby Linchpin received an up-to $45 million loan from LI Lending of which $48,300 was outstanding as of December 31, 2021. Mr. Gontmakher, the CEO of the Company, and Roman Tkachenko, a director of the Company, each hold
a 14.28
% ownership interest in LI Lending. Additionally, Mr. Tkachenko is a managing member of LI Lending. LI Lending has advanced the Company a real estate improvement/development loan of
$50,000
under that certain Construction Loan Agreement to be used for the acquisition and development of real estate to be used for cannabis operations. The loan matures in
$49,027 May 2024
and bears interest at 10.25%, payable monthly in cash. Upon maturity, an exit fee of $9 million is payable, for a total payable at maturity of $54 million. of the loan advanced includes the notes payable and accrued interest less debt discount
of $376
that was outstanding as of March 31, 2022. Of the
$49,027 outstanding at March 31, 2022, $1,891
represents interest accrued through March 31, 2022. See Note 9 for details on the outstanding note payable.
Pure Ratios
Leonid Gontmakher, Chief Executive Officer of the Company, holds an interest in an entity related to iWolf Management, LLC, an online marketing company serving the online CBD market which provided online marketing services during 2020 and 2019 for the Company’s Pure Ratios division. Pure Ratios paid
$313
for the three months ended March 31, 2021 to this vendor for management fees, pass through marketing costs and customer service. Pure Ratios did not make any such payments during the three months ended March 31, 2022.
20
4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Three Months Ended March 31, 2022 and 2021 (unaudited)
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
Note 14: CONTINGENCIES
(a) |
Cannabis Industry |
Cannabis is still considered a Schedule 1 substance under the Controlled Substance Act. As such, there is an inherent risk related to the federal government’s position on cannabis; additionally, the risk exists, due to the Company’s business in cannabis, that third party service providers could suspend or withdraw services and as well as the risk that regulatory bodies could impose certain restrictions on the issuer’s ability to operate in the U.S.; however, the Company has deemed it not reasonable to estimate a potential liability related to the possible enforcement of laws against the medical cannabis industry.
(b) |
Contingent consideration payable |
As part of the acquisition of Om of Medicine, LLC and Cannex’s prior acquisition of Pure Ratios, the Company is subject to contingent consideration payable to the sellers. The fair value of the contingent consideration, which is based on specific revenue levels achieved over a period, is as follows:
2-3-year
Om of Medicine |
||||
Balance, December 31, 2021 |
$ | 2,393 | ||
|
|
|||
Balance, March 31, 2022 |
2,393 | |||
Less: current portion |
— | |||
|
|
|||
Long-term portion |
$ | 2,393 |
The contingent consideration payable is measured at fair value based on unobservable inputs and is considered a Level 3 financial instrument. The determination of the fair value of these liabilities is primarily driven by the Company’s expectations of the respective subsidiaries achieving certain milestones. The expected milestones were assigned probabilities and the expected related cash flows were discounted to derive the fair value of the contingent consideration. The remaining balance of contingent consideration as of March 31, 2022 is $2,393
, all of which is a long-term contingent consideration. The contingent consideration payment is due in full in April 2023.
OM of Medicine:
21
4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Three Months Ended March 31, 2022 and 2021 (unaudited)
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
(c) |
Legal Matters |
From time to time, the Company may be involved in certain disputes arising in the ordinary course of business. Such disputes, taken in the aggregate, are not expected to have a material adverse effect on the Company. There are also no proceedings in which any of the Company’s directors, officers, or affiliates is an adverse party or has a material interest adverse to the Company’s interest.
On August 5, 2019, Richard Hernandez and Commerce Citizens Against Marijuana Corruption (the “Complainants”) filed a complaint (Superior Court of California Case No. and writ of mandamus against the City of Commerce, California and certain of its officials alleging procedural errors committed by the City in relation to certain development agreements granted to 22 cannabis operators allowing such operators to operate various cannabis businesses in the City of Commerce. Cannex Holdings (California), Inc., a wholly owned subsidiary of the Company, is one such operator that was named as a Real Party in Interest in the case, and as such, engaged counsel to defend its interests relating to the claims brought against the City of Commerce, California. On April 15, 2021, the court in the matter ruled on a demurrer where certain of the Complainants’ claims were dismissed. Additionally, a writ of mandamus hearing (subject to an application for continuance being sought on August 17, 2021) was scheduled for September 30, 2021. If the Complainants’ remaining claims were upheld (including through appeals), the City of Commerce could have been required to reissue the “ordinances”, “Development Agreements” or other applicable license rights to the current license holders. While the City of Commerce stated in no uncertain terms that it would act immediately to ensure/restore fully licensed status of any of the affected operators, there could be no assurances that such relicensing would be successful or if successful would not result in a significant disruption of operations for the operators. As a result, the Company entered into a confidential settlement with Complainants on or around September 22, 2021 and the matter was dismissed with prejudice as to the Company.
19ST-CV-27029)
In December 2021, the Company settled a dispute with an undisclosed defendant. As part of the settlement, the Company recorded a gain on the settlement of $3,768.
On January 26, 2022, Savills, Inc. sued the Company in the U.S. District Court for the Southern District of New York. That lawsuit alleges that the Company has breached an alleged agreement with Savills under which the Company was allegedly required to pay Savills a percentage of savings realized under certain incentive programs offered in some jurisdictions, which Savills would assist the Company in obtaining. Savills claims damages of approximately $19,000 in connection with its claim that it obtained benefits for the Company allegedly valued at over $129,000. The Company denies these allegations, denies the Company has obtained such benefits, disputes Savills’ characterization of the facts, and denies liability. The Company has filed a counterclaim against Savills alleging breach of contract by Savills.
Note 15: FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT
ASC 820, Fair Value Measurements, provides guidance on the development and disclosure of fair value measurements. The Company follows this authoritative guidance for fair value measurements, which defines fair value, establishes a framework for measuring fair value under generally accepted accounting principles in the United States of America, and expands disclosures about fair value measurements. The guidance requires fair value measurements be classified and disclosed in one of the following three categories:
22
4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Three Months Ended March 31, 2022 and 2021 (unaudited)
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
Level 1 | Quoted prices (unadjusted) in active markets for identical assets or liabilities; | |
Level 2 | Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices); and | |
Level 3 | Inputs for the asset or liability that are not based on observable market data (unobservable inputs). |
Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of and during the periods ended March 31, 2022 and December 31, 2021. The fair value of the Company’s cash, accounts receivable, other receivables, accounts payable and accrued expenses approximates carrying value due to their short-term nature. The Company’s notes receivable, lease receivables, contingent consideration payable, derivative liabilities, convertible notes payable, construction finance liability, and notes payable approximate fair value due to the instruments bearing market rates of interest or their short-term nature. As the interest rates utilized to calculate these instruments approximates market value interest rates, the carrying amounts of the instruments approximate fair value, which are primarily based on Level 1 inputs. The fair value of stock options granted were estimated based on a Black-Scholes model during the periods ended March 31, 2022 and December 31, 2021. The estimated fair value of the derivative liabilities, which represent embedded put included in the convertible notes payable, represent Level 3 measurements.
The following table details the fair value measurements within the fair value hierarchy of the Company’s financial instruments, which includes the Level 3 liabilities:
Fair value at March 31, 2022 |
||||||||||||||||
Total |
Level 1 |
Level 2 |
Level 3 |
|||||||||||||
Liabilities: |
||||||||||||||||
Derivative liability |
$ | 2,202 | $ | — | $ | — | $ |
2,202 | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Total liabilities |
$ | 2,202 | $ | — | $ | — | $ | 2,202 | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Fair value at December 31, 2021 |
||||||||||||||||
Total |
Level 1 |
Level 2 |
Level 3 |
|||||||||||||
Liabilities: |
||||||||||||||||
Derivative liability |
$ | 3,502 | $ | — | $ | — | $ | 3,502 | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Total liabilities |
$ | 3,502 | $ | — | $ | — | $ | 3,502 | ||||||||
|
|
|
|
|
|
|
|
The table below provides a summary of the changes in fair value of the derivative liabilities measured on a recurring basis using significant unobservable inputs (Level 3):
For the Three Months Ended March 31, |
||||||||
2022 |
2021 |
|||||||
Derivative liability: |
||||||||
Balance, beginning of period |
$ | 3,502 | $ | 5,807 | ||||
(Gain) loss on fair value of derivative liability |
(1,300 | ) | 2,532 | |||||
|
|
|
|
|||||
Balance, end of period |
$ | 2,202 | $ | 8,339 | ||||
|
|
|
|
There were no transfers
23
4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Three Months Ended March 31, 2022 and 2021 (unaudited)
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
(a) |
Financial Risk Management |
The Company is exposed in varying degrees to a variety of financial instruments related risks. The Board mitigates these risks by assessing, monitoring and approving the Company’s risk management processes.
(b) |
Credit Risk |
Credit risk is the risk of loss associated with a counterparty’s inability to fulfill its payment obligations. The Company’s credit risk is primarily attributable to cash, lease receivables, other receivables, and notes receivable. The Company’s maximum credit risk exposure is equivalent to the carrying value of these instruments.
The risk exposure is limited to the carrying amounts at the statement of financial position date. The risk to cash deposits is mitigated by holding these instruments with regulated financial institutions. Lease receivables, notes receivables and other receivables credit risk arises from the possibility that principal and interest due may become uncollectible. The Company mitigates this risk by managing and monitoring the underlying business relationships.
The Company maintains cash with federally insured financial institutions. As of December 31, 2021, the Company exceeded federally insured limits by approximately
$10,866
. The Company did not exceed any federally insured limits at any of its financial institutions for the three months ended March 31, 2022. The Company has historically not experienced any losses in such accounts. As of March 31, 2022, the Company held approximately
$29 in cash in a Canadian account that is denominated in C$.
As of March 31, 2022 and December 31, 2021, the maximum credit exposure related to the carrying amounts of accounts receivable, other receivables, notes receivable and lease receivables was
$14,725 and $12,722, respectively.
(c) |
Liquidity Risk |
Liquidity risk is the risk that the Company will not be able to meet its financial obligations associated with financial liabilities. The Company manages liquidity risk through the management of its capital structure. The Company’s approach to managing liquidity is to raise sufficient capital to settle obligations and liabilities when due.
The Company has the following gross contractual obligations as of March 31, 2022, which are expected to be payable in the following respective periods:
Less than 1 year |
1 to 3 years |
3 to 5 years |
Greater than 5 years |
Total |
||||||||||||||||
Accounts payable and accrued liabilities |
$ | 12,706 | $ | 1,200 | $ | — | $ | — | $ | 13,906 | ||||||||||
Convertible notes, notes payable and accrued interest |
5,385 | 65,280 | — | — | 70,665 | |||||||||||||||
Contingent consideration payable |
— | 2,393 | — | — | 2,393 | |||||||||||||||
Construction finance liability |
|
|
— |
|
|
|
16,000 |
|
|
|
— |
|
|
|
— |
|
|
$ |
16,000 |
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
Total |
$ | 18,091 | $ | 84,873 | $ | — | $ | — | $ | 102,964 | ||||||||||
|
|
|
|
|
|
|
|
|
|
24
4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Three Months Ended March 31, 2022 and 2021 (unaudited)
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
(d) |
Interest Rate Risk |
Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates.
(e) |
Foreign Exchange Risk |
The Company is exposed to exchange rate fluctuations between United States and Canadian dollars. The Company’s share price is denominated in Canadian dollars. If the Canadian dollar declines against the United States dollar, the United States dollar amounts available to fund the Company through the exercise of stock options or warrants will be less. The Company also has bank accounts with balances of $29 in Canadian dollars. The value of these bank balances if converted to U.S. dollars will fluctuate. While the Company maintains a head office in Canada where it incurs expenses primarily denominated in Canadian dollars, such expenses are a small portion of overall expenses incurred by the Company. The Company does not have a practice of trading derivatives and does not engage in “natural hedging” for funds held in Canada.
(f) |
Other Price Risk |
Price risk is the risk of variability in fair value due to movements in equity or market prices. The Company is subject to risk of prices to its products due to competitive or regulatory pressures.
Note 16: SEGMENT INFORMATION
Reportable Segments
Operating segments are components of the Company that combine similar business activities, with activities grouped to facilitate the evaluation of business units and allocation of resources by the Company’s board of directors and management. As of March 31, 2022, the
Company had two reportable segments:
• | THC Cannabis – Production and cultivation of THC cannabis, manufacturing and distribution of cannabis products to own dispensaries and third-party retail customers, ancillary services supporting wholesale operations, and retail sales direct to end consumers |
• | CBD Wellness – Pure Ratios which encompasses the production and sale of CBD products to third-party customers |
The results of each segment are regularly reviewed by the Company’s Chief Executive Officer, who is the Company’s chief operating decision maker, to assess the performance of the segment and make decisions regarding the allocation of resources. The Company’s chief operating decision maker uses revenue and net loss as measure of segment performance. There are no intersegment sales or transfers. All revenues are derived from customers domiciled in the United States and all assets are located in the United States.
The below table presents revenues by type for the three months ended March 31, 2022 and 2021:
25
4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Three Months Ended March 31, 2022 and 2021 (unaudited)
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
Three Months Ended March 31, |
||||||||
2022 |
2021 |
|||||||
Net Revenues |
||||||||
THC Cannabis |
$ | 25,783 | $ | 22,148 | ||||
CBD Wellness |
265 | 822 | ||||||
Corporate |
— | — | ||||||
|
|
|
|
|||||
Total Net Revenues |
26,048 | 22,970 | ||||||
Depreciation and Amortization |
||||||||
THC Cannabis |
847 | 756 | ||||||
CBD Wellness |
— | 16 | ||||||
Corporate |
— | 2 | ||||||
|
|
|
|
|||||
Total Depreciation and amortization |
847 | 774 | ||||||
Net (Income) Loss |
||||||||
THC Cannabis |
256 | 2,838 | ||||||
CBD Wellness |
(15 | ) | 3 | |||||
Corporate |
5,658 | 8,247 | ||||||
|
|
|
|
|||||
Total Net Loss |
$ | 5,899 | $ | 11,089 |
Assets |
March 31, 2022 |
December 31, 2021 |
||||||
THC Cannabis |
$ | 286,461 | $ | 238,933 | ||||
CBD Wellness |
725 | 805 | ||||||
Corporate |
3,503 | 15,801 | ||||||
|
|
|
|
|||||
Total Assets |
$ |
290,689 |
$ |
255,539 |
On January 28, 2022, the Company acquired assets and liabilities from NECC and 29 Everett in conjunction with the NECC Merger Agreements. As part of the acquisition, the Company acquired $
18,000
in intangible assets related to the licenses acquired from NECC, and recognized goodwill of $10,249
as part of the purchase price consideration. The Company also consolidated revenues and net loss from NECC from the acquisition date of January 28, 2022 through the period end date of March 31, 2022. For further details on the acquisition of NECC and 29 Everett, see Note 7. The Company concluded that as of the date of acquisition, that NECC would be recognized under the THC Cannabis segment as part of segment reporting. Goodwill assigned to the THC Cannabis segment as of March 31, 2022 and December 31, 2021 was $33,404 and
$23,155
, respectively. Intangible assets, net assigned to the THC Cannabis segment as of March 31, 2022 and December 31, 2021 were
$43,616 and $26,246, respectively.
The Company did not have any Goodwill or intangible assets assigned to the CBD Wellness segment as of March 31, 2022 and December 31, 2021.
Note 17: SUPPLEMENTARY CASH FLOW INFORMATION
Changes in
non-cash
working capital: 26
4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Three Months Ended March 31, 2022 and 2021 (unaudited)
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
March 31, 2022 |
March 31, 2021 |
|||||||
Changes in operating assets and liabilities |
||||||||
Accounts receivable and other receivables |
$ | (2,309 | ) | $ | 100 | |||
Inventory |
(3,823 | ) | (934 | ) | ||||
Prepaid expenses |
153 | (830 | ) | |||||
Deposits |
257 | (460 | ) | |||||
Accounts payable and accrued liabilities |
778 | 1,393 | ||||||
Taxes payable |
3,651 | 1,806 | ||||||
|
|
|
|
|||||
$ | (1,293 | ) | $ | 1,075 | ||||
|
|
|
|
Supplemental disclosure of
non-cash
investing and financing activities: March 31, 2022 |
March 31, 2021 |
|||||||
Exchange of convertible debt to equity |
$ |
3,122 | $ | — | ||||
|
|
|
|
|||||
Change in right-of-use assets and lease liabilities |
$ |
77 | $ | — | ||||
|
|
|
|
|||||
Issuance of equity for NECC pursuant to acquisition |
$ |
17,689 |
$ |
— |
||||
Property, plant, and equipment acquired through NECC acquisition |
$ |
15,238 |
$ |
— |
||||
Issuance of notes payable in through NECC acquisition |
$ |
2,000 |
$ |
— |
||||
Inventory acquired through NECC acquisition |
$ |
2,000 |
$ |
— |
• | Cash paid for interest for the three months ended March 31, 2022 and 2021 was $1,569 and $818 , respectively. |
• | Cash paid for income taxes for the three months ended March 31, 2022 and 2021 was $1,110 and $224 , respectively. |
Note 18: INCOME TAXES
The following table summarizes the Company’s income tax expense:
For the Three Months Ended March 31, |
||||||||
2022 |
2021 |
|||||||
Net loss before income taxes |
$ | (2,456 | ) | $ | (8,431 | ) | ||
Income tax expense |
(3,438 | ) | (2,653 | ) |
The Company has computed its provision for income taxes under the discrete method which treats the
year-to-date
period
as if it were the annual period and determines the income tax expense or benefit on that basis. The discrete method is applied when application of the estimated annual effective tax rate is impractical because it is not possible to reliably estimate the annual effective tax rate. The Company believes the use of this discrete method is more appropriate than the annual effective tax rate method due to the early growth stage of the business. At this time, there is a high degree of uncertainty in estimating the Company’s annual pre-tax
income and significant non-deductible
expenses so the Company cannot reliably estimate the annual effective tax rate. Internal Revenue Code (“IRC”) Section 280E denies, at the U.S. federal level, deductions, and credits attributable to a trade or business trafficking in controlled substances. Because the Company is subject to IRC Section 280E, the Company has computed its U.S. tax based on gross receipts less cost of goods sold. The tax provisions for the three months ended March 31, 2022 and 2021, have been prepared based on the assumption that cost of goods sold is a valid expense for income tax purposes.
27
4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Three Months Ended March 31, 2022 and 2021 (unaudited)
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
The federal statute of limitation remains open for the
2018 tax year to the present. The state income tax returns generally remain open for the
2017 tax year through the present. Net operating losses arising prior to these years are also open to examination if and when utilized.
Note 19: SUBSEQUENT EVENTS
On March 30, 2022, the Company entered into an agreement and plan of merger (the “Island Merger Agreement”) by and among the Company, Island Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Island Merger Sub”); Island Global Holdings, Inc., a California corporation (“Island”); and Navy Capital SR LLC, a Delaware limited liability company (“Navy”, and together with the Company, Island Merger Sub, and Island, the “Island Parties”). Pursuant to the terms and conditions of the Merger Agreement, Island Merger Sub will be merged with and into Island, with Island surviving the merger and continuing its corporate existence as a wholly owned subsidiary of the Company (the “Island Merger”). The Island Merger Agreement was effective as of April 13, 2022 (the “Effective Date”).
On the Effective Date, the Island Parties consummated the Island Merger, pursuant to the terms and conditions of the Island Merger Agreement, as amended. However, due to administrative and technical issues at the California Office of the Secretary of State, the Island Parties did not receive the certificate of merger evidencing the closing of the Island Merger as of the Effective Date until April 25, 2022. At the Effective Date, pursuant to the terms and conditions of the Island Merger Agreement, as amended, the Company issued to certain shareholders and debtholders of Island an aggregate of:
54
-month, subordinated promissory notes (the “Island Merger Notes”) in the aggregate principal amount of
On April 22, 2022, the Parties entered into the first amendment to the Island Merger Agreement to replace the requirement that certain noteholders fund a letter of credit to Island of up to
$1,000,000
. In lieu of funding a line of credit, the noteholders agreed to pay the full
$1,000,000
The Company is in the process of assessing the fair values of the acquired tangible assets and any intangible assets and liabilities for these acquisitions, and thus, have not presented purchase price allocations as of the date of this filing.
28
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
This Quarterly Report on Form
10-Q
contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally relate to future events or our future financial or operating performance and may include statements concerning, among other things, our business strategy (including anticipated trends and developments in, and management plans for, our business and the markets in which we operate), financial results, the impact of COVID-19
on our business, operations, and the markets and communities in which we, our clients, and partners operate, results of operations, revenues, operating expenses, and capital expenditures, sales and marketing initiatives and competition. In some cases, you can identify forward-looking statements because they contain words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “suggests,” “potential” or “continue” or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. These statements are not guarantees of future performance; they reflect our current views with respect to future events and are based on assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, performance, or achievements to be materially different from expectations or results projected or implied by forward-looking statements. We discuss many of these risks in other filings we make from time to time with the Securities and Exchange Commission (the “SEC”). Also, these forward-looking statements represent our estimates and assumptions only as of the date of this Quarterly Report on Form
10-Q,
which are inherently subject to change and involve risks and uncertainties. Unless required by federal securities laws, we assume no obligation to update any of these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated, to reflect circumstances or events that occur after the statements are made. Given these uncertainties, investors should not place undue reliance on these forward-looking statements. Investors should read this Quarterly Report on Form
10-Q
and the documents that we reference in this report and have filed with the SEC and on SEDAR, including our Annual Report on Form 10-K,
filed with the SEC on April 18, 2022, with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements for the three months ended March 31, 2022 and 2021. Unless the context otherwise indicates, when used in this Quarterly Report on Form
10-Q,
“4Front,” “the Company,” “we,” “us” and “our” refer to 4Front Ventures Corp., a British Columbia corporation, and its wholly owned subsidiaries on a consolidated basis. Overview
4Front Ventures Corp. (“4Front” or the “Company”) exists pursuant to the provisions of the British Columbia Corporations Act. On July 31, 2019, 4Front Holdings LLC (“Holdings”) completed a Reverse Takeover Transaction (“RTO”) with Cannex Capital Holdings Inc. (“Cannex”) whereby Holdings acquired Cannex and the shareholders of Holdings became the controlling shareholders of the Company. Following the RTO, the Company’s SVS are listed on the Canadian Securities Exchange (“CSE”) under the ticker “FFNT” and are quoted on the OTC (OTCQX: FFNTF).
The Company has two primary operating segments: THC Cannabis and CBD Wellness. With regard to its THC Cannabis segment, as of March 31, 2022, the Company operates six dispensaries in Massachusetts, Illinois, and Michigan, primarily under the “MISSION” brand name. As of March 31, 2022, the Company operates three production facilities in Massachusetts, Illinois and California and produces the majority of products that are sold at its own Massachusetts, Illinois, and California dispensaries. Also, as part of its THC Cannabis segment, the Company leases real estate and sells equipment, supplies and intellectual property to cannabis producers in the state of Washington.
While marijuana is legal under the laws of several U.S. states (with varying restrictions), the United States Federal Controlled Substances Act classifies all “marijuana” as a Schedule I drug, whether for medical or recreational use. Under U.S. federal law, a Schedule I drug or substance has a high potential for abuse, no accepted medical use in the United States, and a lack of safety for the use of the drug under medical supervision.
The Company’s CBD Wellness segment is focused upon its ownership and operation of its wholly owned subsidiary, Pure Ratios Holdings, Inc. (“Pure Ratios”), a CBD-focused wellness company in California, that sells non-THC products throughout the United States.
29
Recent Developments
Merger with Island Global Holdings, Inc.
On March 30, 2022, the Company entered into an agreement and plan of merger (the “Island Merger Agreement”) by and among the Company, Island Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Island Merger Sub”); Island Global Holdings, Inc., a California corporation (“Island”); and Navy Capital SR LLC, a Delaware limited liability company (“Navy”, and together with the Company, Island Merger Sub, and Island, the “Island Parties”). Pursuant to the terms and conditions of the Island Merger Agreement, Island Merger Sub will be merged with and into Island, with Island surviving the merger and continuing its corporate existence as a wholly owned subsidiary of the Company (the “Island Merger”). The Island Merger Agreement was effective as of April 13, 2022 (the “Effective Date”).
On the Effective Date, the Island Parties consummated the Island Merger, pursuant to the terms and conditions of the Island Merger Agreement, as amended. However, due to administrative and technical issues at the California Office of the Secretary of State, the Island Parties did not receive the certificate of merger evidencing the closing of the Island Merger as of the Effective Date until April 25, 2022. At the Effective Date, pursuant to the terms and conditions of the Island Merger Agreement, as amended, the Company issued to certain shareholders and debtholders of Island an aggregate of: (i) 8,783,716 Class A Subordinated Voting Shares of the Company (the “SVS”); (ii) 6% 54-month, subordinated promissory notes (the “Island Merger Notes”) in the aggregate principal amount of $6,500,000; and (iii) warrants to purchase 2,999,975 SVS at a price of $1.00 per SVS (the “Warrants”, and together with the SVS and Island Merger Notes, the “Island Merger Consideration”).
On April 22, 2022, the Parties entered into the first amendment to the Island Merger Agreement to replace the requirement that certain noteholders fund a letter of credit to Island of up to $1,000,000. In lieu of funding a line of credit, the noteholders agreed to pay the full $1,000,000 in cash to Island on or prior to the closing of the transactions contemplated by the Island Merger Agreement.
Merger with New England Cannabis Corporation
Please see Note 7 of the financial statements for a full description of the Company’s entrance into the NECC Merger Agreement on October 6, 2021, and related transactions.
Healthy Pharms Inc. Settlement Agreement
On January 14, 2022, the Company and Healthy Pharms Inc. entered into a settlement agreement to settle the unsecured promissory note with an outstanding balance of $3,213 at December 31, 2021, in SVS and the Company issued a total of 6,235,512 SVS.
Changes to Composition of Board of Directors
On January 28, 2022, Eric Rey resigned as a member of the Company’s board of directors (the “Board”) and committees of the Board of the Company. Mr. Rey’s resignation was not in connection with any known disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.
Mr. Rey served as the chairman of the Board’s audit committee. As a result of Mr. Rey’s resignation, the Board appointed current Board member David Daily as chairperson of the Company’s audit committee, effective as of February 2, 2022.
Effective April 12, 2022, the Company’s Board appointed Mr. Amit Patel and Mr. Robert E. Hunt as members of the Board.
Mr. Patel and Mr. Hunt were elected to serve as directors of the Board until the Company’s 2022 annual meeting of stockholders and until their successors are elected and qualified or until their earlier resignation or removal.
The Board has determined that Mr. Patel and Mr. Hunt are “independent” directors under the rules of the Securities and Exchange Commission and the listing standards of The Nasdaq Stock Market, LLC.
There are no arrangements or understandings between Mr. Patel or Mr. Hunt and any other persons pursuant to which they were elected as a director. Mr. Patel and Mr. Hunt do not have any family relationships with any of the Company’s directors or executive officers. There are no transactions and no proposed transactions between Mr. Patel or Mr. Hunt and the Company that would be required to be disclosed pursuant to Item 404(a) of
Regulation S-K.
Mr. Patel and Mr. Hunt were not initially appointed to serve on any committees of the Board. Furthermore, until Messrs. Patel and Hunt are approved by state regulators, they will be recused from decisions regarding operations and strategic planning, capital allocations, acquisitions, and divestments concerning assets in states where director approval is required.
Effective April 25, 2022, the Board accepted David Daily’s resignation from his position as chairman of the audit committee. Mr. Daily will continue to serve as a member of the audit committee, as well as a member of the Board. Also effective April 25, 2022, the Board appointed Mr. Patel as both a member and chairman of its audit committee.
The Board has determined that as well as being an independent director, Mr. Patel qualifies as an “audit committee financial expert,” as such term is defined in Item 407(d)(5)(ii) of Regulation S-K.
Interim Chief Financial Officer
Effective July 15, 2021, the Company’s board of directors appointed Andrew Thut as the Company’s Interim Chief Financial Officer while the Company continues its search for a permanent Chief Financial Officer. Mr. Thut joined the Company in October 2014 as its Chief Investment Officer and will continue to serve as Chief Investment Officer during his tenure as Interim Chief Financial Officer of the Company. The Company’s search for a permanent Chief Financial Officer was
on-going
as of the date of this Quarterly Report on Form 10-Q.
COVID-19
Pandemic In March 2020, the World Health Organization (“WHO”) declared
COVID-19
a global pandemic and the United States declared a national emergency with respect to COVID-19.
The emergence of COVID-19,
an extremely infectious airborne respiratory virus, caused a significant response on the part of many governments to contain it. 30
The full extent of the
COVID-19
pandemic impact continues to depend on future developments that remain highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19,
the actions taken to contain it or treat its impact, the identification and spread of COVID-19
variants such as the Delta and the Omicron variants, the distribution of vaccines, the acceptance of vaccines and the implementation of vaccine mandates, and the economic impact on local, regional, national and international markets. Management continues to actively monitor the developments regarding the pandemic and the impact that the pandemic could have on our business, results of operations, financial condition, and most importantly the health and safety of our workforce. Given the continued volatility of the COVID-19
pandemic and the global responses to curb its spread, we are not able to estimate the effects of the COVID-19
pandemic on our results of operations, financial condition, or liquidity for 2022. Any recovery from negative impacts to our business and related economic impact due to the COVID-19
pandemic may also be slowed or reversed by a number of factors, including the current widespread resurgence in COVID-19
infections attributable to the Omicron variant, combined with the seasonal flu. As such, we are unable to reasonably estimate the duration of the pandemic or fully ascertain its long-term impact to our business. War in Ukraine
In February 2022, the Russian Federation and Belarus commenced a military action with the country of Ukraine. As a result of this action, various nations, including the United States, have instituted economic sanctions against the Russian Federation and Belarus. Further, the impact of this action and related sanctions on the world economy are not determinable as of the date of these financial statements. The specific impact on our financial condition, results of operations, and cash flows is also not determinable as of the date of these financial statements.
Critical Accounting Policies and use of Estimates
Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which we have prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). We believe that several accounting policies are important to understanding our historical and future performance. We refer to these policies as critical because these specific areas generally require us to make judgments and estimates about matters that are uncertain at the time we make the estimate, and different estimates – which also would have been reasonable – could have been used. On an ongoing basis, we evaluate our estimates and judgments, including those described in greater detail below. We base our estimates on historical experience and other market-specific or other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
Critical accounting policies and estimates are further discussed in our Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the SEC on April 18, 2022.
Results of Operations
Three Months Ended March 31, 2022 Compared With Three Months Ended March 31, 2021
The following table sets forth our consolidated statement of operations for the three months ended March 31, 2022 and 2021, and the change between the two years ($ in thousands):
31
For the Three Months Ended March 31, |
Change |
|||||||||||||||
2022 |
2021 |
$ |
% |
|||||||||||||
Revenue from Sale of Goods |
$ | 23,083 | $ | 20,080 | $ | 3,003 | 15 | % | ||||||||
Real Estate Income |
2,965 | 2,890 | 75 | 3 | % | |||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total Revenues |
26,048 | 22,970 | 3,078 | 13 | % | |||||||||||
Cost of Goods Sold |
(12,594 | ) | (9,125 | ) | (3,469 | ) | 38 | % | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Gross profit |
13,454 | 13,845 | (391 | ) | 3 | % | ||||||||||
Total Operating Expense |
14,695 | 13,492 | 1,203 | 9 | % | |||||||||||
|
|
|
|
|
|
|
|
|||||||||
Income (Loss) from Operations |
(1,241 | ) | 353 | (1,594 | ) | 452 | % | |||||||||
Total Other income (expense), net |
(1,215 | ) | (8,784 | ) | 7,569 | 86 | % | |||||||||
|
|
|
|
|
|
|
|
|||||||||
Net Loss Before Income Taxes |
(2,456 | ) | (8,431 | ) | 5,975 | 71 | % | |||||||||
Income Tax Expense |
(3,438 | ) | (2,653 | ) | (785 | ) | 30 | % | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Net Loss from Continuing Operations |
(5,894 | ) | (11,084 | ) | 5,190 | 47 | % | |||||||||
|
|
|
|
|
|
|
|
|||||||||
Net Loss |
$ | (5,894 | ) | $ | (11,084 | ) | $ | 5,190 | 47 | % | ||||||
|
|
|
|
|
|
|
|
Revenue from Sale of Goods
Revenue from sale of goods for the three months ended March 31, 2022 was $23,083, an increase of $3,003 or 15% compared to the three months ended March 31, 2021. This increase is primarily due to increased revenue from the Company’s Brookline, MA and Calumet City, IL dispensaries as well as an increase in the Company’s wholesale revenue.
Real Estate Income
Real Estate Income from leasing cannabis production facilities for the three months ended March 31, 2022 was $2,965, an increase of $75 or 3% which is relatively flat compared to the $2,890 recognized for the three months ended March 31, 2021.
Cost of Goods Sold
Cost of goods sold (“COGS”) increased by $3,469 for the three months ended March 31, 2022. COGS represent costs to cultivate and produce cannabis and CBD products that are produced in our owned facilities and are sold to third parties and through our owned dispensaries. For products that are purchased from third parties, COGS is the cost of inventory for sales to retail customers. This increase in COGS is largely attributed to increased third party purchases to meet consumer demand at the Company’s retail locations.
32
Gross Profit
Gross profit for the three months ended March 31, 2022 was $13,454 or 52% of revenue compared to $13,845 or 60% of revenue for the three months ended March 31, 2021. The decrease in gross profit percentage of 8% is primarily due to increases in third party inventory purchases, particularly to meet exceptional consumer demand in IL, as well as some anticipated pricing pressure in the Massachusetts market.
Total Operating Expenses
Total operating expenses for the three months ended March 31, 2022 were $14,695, an increase of $1,203 or 9%, as compared to the three months ended March 31, 2021. This increase is primarily due to an increase in general and administrative expenses of $2,479, offset by a decrease in equity based compensation of $1,358.
Total Other Income (Expense), net
Total Other Income (Expense) for the three months ended March 31, 2022 was $1,215, as compared to $8,784 for the three months ended March 31, 2021. This is primarily driven by a decrease in non-cash expenses including amortization of loan discount and change in fair value of derivative liability.
Net Loss From Continuing Operations
Net loss from continuing operations for the three months ended March 31, 2022 was $5,894, compared to a net loss from continuing operations of $11,084 for the three months ended March 31, 2021.
Non-GAAP
Financial and Performance Measures In addition to providing financial measurements based on GAAP, we provide additional financial metrics that are not prepared in accordance with GAAP. Management uses
non-GAAP
financial measures, in addition to GAAP financial measures, to understand and compare operating results across accounting periods, for financial and operational decision making, for planning and forecasting purposes and to evaluate the Company’s financial performance. Management uses the non-GAAP
measurement of adjusted EBITDA, which we believe reflects our ongoing business in a manner that allows for meaningful comparisons and analysis of trends in the business, as it facilitates comparing financial results across accounting periods. We also believe that this non-GAAP
financial measure enables investors to evaluate the Company’s operating results and future prospects in the same manner as management. This non-GAAP
financial measures may also exclude expenses and gains that may be unusual in nature, infrequent or not reflective of the Company’s ongoing operating results. As there are no standardized methods of calculating non-GAAP
measures, our methods may differ from those used by others, and accordingly, the use of these measures may not be directly comparable to similarly titled measures used by others. Accordingly, non-GAAP
measures are intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with GAAP. 33
Adjusted EBITDA
Adjusted EBITDA is a financial measure that is not calculated in accordance with U.S. GAAP. Management believes that because adjusted EBITDA excludes (a) certain
non-cash
expenses (such as depreciation, amortization and stock-based compensation) and (b) expenses that are not reflective of the Company’s core operating results over time (such as restructuring costs, litigation or dispute settlement charges or gains, and transaction-related costs), this measure provides investors with additional useful information to measure the Company’s financial performance, particularly with respect to changes in performance from period to period. The Company’s management uses adjusted EBITDA (a) as a measure of operating performance, (b) for planning and forecasting in future periods, and (c) in communications with the Company’s board of directors concerning the Company’s financial performance. The Company’s presentation of adjusted EBITDA is not necessarily comparable to other similarly titled captions of other companies due to different methods of calculation and should not be used by investors as a substitute or alternative to net loss or any measure of financial performance calculated and presented in accordance with U.S. GAAP. Instead, management believes adjusted EBITDA should be used to supplement the Company’s financial measures derived in accordance with U.S. GAAP to provide a more complete understanding of the trends affecting the business. Although adjusted EBITDA is frequently used by investors and securities analysts in their evaluations of companies, adjusted EBITDA has limitations as an analytical tool, and investors should not consider it in isolation or as a substitute for, or more meaningful than, amounts determined in accordance with U.S. GAAP. Some of the limitations to using
non-GAAP
measures as an analytical tool are (a) they do not reflect the Company’s interest income and expense, or the requirements necessary to service interest or principal payments on the Company’s debt, (b) they do not reflect future requirements for capital expenditures or contractual commitments, and (c) although depreciation and amortization charges are non-cash
charges, the assets being depreciated and amortized will often have to be replaced in the future, and non-GAAP
measures do not reflect any cash requirements for such replacements. Adjusted EBITDA is defined by the Company as earnings before interest, taxes, depreciation and amortization, accretion, share-based compensation expense, legal settlement, change in value of derivative liability, foreign exchange gain (loss), loss on lease termination, other
non-cash
expenses, and one-time
charges related to acquisition costs, financing-related costs, extraordinary pre-opening
expenses and non-recurring
expenses. We consider these measures to be an important indicator of the financial strength and performance of our business. The following table reconciles adjusted EBITDA to its closest GAAP measure.
For the three months ended March 31, 2022 and 2021, adjusted EBITDA consisted of the following:
34
Three months ended March 31, |
2022 |
2021 |
||||||
Net loss (GAAP) |
$ | (5,899 | ) | $ | (11,084 | ) | ||
Interest income |
(2 | ) | (3 | ) | ||||
Interest expense |
4,227 | 2,461 | ||||||
Amortization of loan discount upon conversion of debt to equity |
— | 2,915 | ||||||
Income tax expense |
3,438 | 2,653 | ||||||
Depreciation and amortization |
1,795 | 1,046 | ||||||
Accretion |
3,706 | — | ||||||
Equity based compensation |
1,038 | 2,396 | ||||||
Change in value of derivative liability |
(1,300 | ) | 2,532 | |||||
Acquisition, transaction, and other one-time costs |
891 | 1,496 | ||||||
Non-cash lease expense |
1,125 | 612 | ||||||
Loss on lease termination |
— | 879 | ||||||
|
|
|
|
|||||
Adjusted EBITDA (Non-GAAP) |
9,018 | $ | 5,903 | |||||
|
|
|
|
Adjusted EBITDA should not be considered in isolation from, or as a substitute for, net loss. There are a number of limitations related to the use of adjusted EBITDA as compared to net loss, the closest comparable GAAP measure. Adjusted EBITDA excludes:
• | Interest income and expense |
• | Current income tax expense |
• | Non-cash depreciation and amortization expense |
• | Accretion expense related to a periodic update of the present value of a liability |
• | Equity based compensation expense, which has been, and will continue to be for the foreseeable future, a significant recurring expense in our business and an important part of our compensation strategy |
• | Legal settlements |
• | Non-cash change in fair value of derivative liability |
• | Acquisition, transaction, and other expenses (income), which vary significantly by transaction and are excluded to evaluate ongoing operating results |
Liquidity and Capital Resources
As of March 31, 2022 and December 31, 2021, we had total current liabilities of $51,612 and $48,838, respectively, and current assets of $43,809 and $50,874, respectively, to meet our current obligations. As of March 31, 2022, we had working deficit of $7,803, compared to working capital of $2,036, as of December 31, 2021. The decrease of $9,839 is driven primarily by a decrease in cash and increases in accounts payable, taxes payable and current portion of notes payable and accrued interest, partially offset by increases in accounts receivable, other receivables, and inventory, and decreases in accrued expenses and other current liabilities, derivative liability, and current portion of convertible notes.
35
The Company is an early-stage growth company. It is generating cash from sales and is deploying its capital reserves to acquire and develop assets capable of producing additional revenues and earnings over both the immediate and near term. Capital reserves are being utilized for capital expenditures and improvements in existing facilities, product development and marketing, as well as customer, supplier and investor and industry relations.
Cash Flows
Net Cash (Used in) Provided by Operations
Net cash used in operating activities was $2,368 for the three months ended March 31, 2022, a decrease of $5,182 as compared to $2,814 of net cash provided by operating activities for the three months ended March 31, 2021. The decrease is primarily due to a gain recognized on the fair valuation of the Company’s derivative liability compared to a loss in the prior period, a decrease in equity based compensation, and a prior period amortization of loan discount upon conversion of debt to equity, which was a one-time expense that was not incurred during the three months ended March 31, 2022. Additionally, the Company’s investments in working capital to build the California and Massachusetts wholesale business resulted in a decrease in net working capital of $1,293.
Net Cash Used in Investing Activities
Net cash used in investing activities was $26,009 for the three months ended March 31, 2022, an increase of $19,979 as compared to $6,030 of cash used in investing activities for the three months ended March 31, 2021. The increase is primarily due to cash paid by the Company as part of the NECC acquisition for the three months ended March 31, 2022. The Company did not enter into an acquisition during the three months ended March 31, 2021. This increase is partially offset by more purchases of property and equipment by the Company during the three months ended March 31, 2021 than the three months ended March 31, 2022.
Net Cash Provided by Financing Activities
Net cash provided by continued financing activities was $14,434 for the three months ended March 31, 2022, an increase of $12,344 as compared to $2,090 of cash provided by financing activities for the three months ended March 31, 2021. The increase is primarily attributed to proceeds from the failed sale-leaseback transaction associated with the NECC acquisition during the three months ended March 31, 2022.
36
Off-Balance
Sheet Arrangements We do not have any
off-balance
sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources. Critical Accounting Policies
We review new accounting standards as issued. Although some of these accounting standards issued or effective after the end of our previous fiscal year may be applicable to the Company, we have not identified any standards that we believe merit further discussion. We do not expect the adoption of any recently issued accounting pronouncements to have a significant impact on our financial position, results of operations, or cash flows.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
As a “smaller reporting company” as defined by Item 10 of Regulation
S-K,
the Company is not required to provide information required by this Item. Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
As required by Rule
13a-15
under the Exchange Act, our management has carried out an evaluation, with the participation and under the supervision of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of March 31, 2022. Disclosure controls and procedures refer to controls and other procedures designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating and implementing possible controls and procedures. Material Weaknesses
A material weakness is a deficiency, or a combination of deficiencies, within the meaning of Public Company Accounting Oversight Board (“PCAOB”) Auditing Standard AS 2201, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.
37
Material Weaknesses in Internal Control
The Company did not fully design and implement effective control activities based on the criteria established in the COSO framework. The Company has identified deficiencies that constitute a material weakness, either individually or in the aggregate. This material weakness is attributable to the following factors:
• | We did not have sufficient accounting staff resources to timely perform closing and audit-related procedures. |
• | We did not have effective controls over the review procedures for balance sheet account reconciliations and manual journal entries. |
• | We did not have documented evidence of review procedures and did not have sufficient segregation of duties within our accounting function. |
Due to the existence of the above material weakness, management, including the CEO and CFO, has concluded that our internal control over financial reporting was not effective as of March 31, 2022. This material weakness creates a reasonable possibility that a material misstatement to the consolidated financial statements will not be prevented or detected on a timely basis.
Management conducted its evaluation of disclosure controls and procedures under the supervision of our CEO and CFO. Based upon, and as of the date of, this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were not effective as of March 31, 2022 due to the material weaknesses listed above.
Remediation of Material Weaknesses in Internal Control over Financial Reporting
The Company continues to strengthen our internal control over financial reporting and is committed to ensuring that such controls are designed and operating effectively. The Company is implementing process and control improvements to address the above material weakness as follows:
• | The Company will assess sufficient resources, both in accounting staff and related technology, needed to timely perform closing and audit-related procedures and align identified resources. |
• | The Company will assess controls needed to effectively review procedures for balance sheet account reconciliations and manual journal entries and implement identified controls. |
• | The Company will assess review procedures to have sufficient segregation of duties within our accounting function, then standardize and document such procedures for evidence of review. |
The material weakness in the Company’s internal control over financial reporting will not be considered remediated until the remediated controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively. The Company is working to have the material weaknesses remediated as soon as possible. However, there is no assurance that the remediation will be fully effective. As described above, the material weakness has not been remediated as of the filing date of this Form
10-Q.
If these remediation efforts do not prove effective and control deficiencies and material weaknesses persist or occur in the future, the accuracy and timing of the Company’s financial reporting may be materially and adversely affected. 38
Inherent Limitations on Effectiveness of Controls
Management recognizes that a control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud or error, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.
Changes in Internal Control over Financial Reporting
Other than those described above, there have been no changes in the Company’s internal control over financial reporting during the three months ended March 31, 2022 that have materially affected, or that are reasonably likely to materially affect, the Company’s internal control over financial reporting.
39
PART II—OTHER INFORMATION
Item 1. Legal Proceedings
On August 5, 2019, Richard Hernandez and Commerce Citizens Against Marijuana Corruption (the “Complainants”) filed a complaint (Superior Court of California Case No. and writ of mandamus against the City of Commerce, California and certain of its officials alleging procedural errors committed by the City in relation to certain development agreements granted to 22 cannabis operators allowing such operators to operate various cannabis businesses in the City of Commerce. Cannex Holdings (California), Inc., a wholly owned subsidiary of the Company, is one such operator that was named as a Real Party in Interest in the case, and as such, engaged counsel to defend its interests relating to the claims brought against the City of Commerce, California. On April 15, 2021, the court in the matter ruled on a demurrer where certain of the Complainants’ claims were dismissed. Additionally, a writ of mandamus hearing (subject to an application for continuance being sought on August 17, 2021) was scheduled for September 30, 2021. If the Complainants’ remaining claims were upheld (including through appeals), the City of Commerce could have been required to reissue the “ordinances”, “Development Agreements” or other applicable license rights to the current license holders. While the City of Commerce stated in no uncertain terms that it would act immediately to ensure/restore fully licensed status of any of the affected operators, there could be no assurances that such relicensing would be successful or if successful would not result in a significant disruption of operations for the operators. As a result, the Company entered into a confidential settlement with Complainants on or around September 22, 2021, and the matter was dismissed with prejudice as to the Company.
19ST-CV-27029)
In December 2021, the Company settled a dispute with an undisclosed defendant. As part of the settlement, the Company recorded a gain on the settlement of $3,768.
On January 26, 2022, Savills, Inc. (“Savills”) sued the Company in the U.S. District Court for the Southern District of New York. That lawsuit alleges that the Company has breached an alleged agreement with Savills under which the Company was allegedly required to pay Savills a percentage of savings realized under certain incentive programs offered in some jurisdictions, which Savills would assist the Company in obtaining. Savills claims damages of approximately $19,000 in connection with its claim that it obtained benefits for the Company allegedly valued at over $129,000. The Company denies these allegations, denies the Company has obtained such benefits, disputes Savills’ characterization of the facts, and denies liability. The Company has filed a counterclaim against Savills alleging breach of contract by Savills.
Apart from the foregoing and ongoing legal proceedings, from time to time, we may be subject to various other legal proceedings and claims that are routine and incidental to our business. Although some of the legal proceedings set forth herein may result in adverse decisions or settlements, management believes that the final disposition of such matters will not have a material adverse effect on our business, financial position, results of operations or cash flows.
Item 1A. Risk Factors
As a “smaller reporting company” as defined by Item 10 of Regulation
S-K,
we are not required to provide information required by this Item. Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
On January 14, 2022, pursuant to a settlement agreement to settle an unsecured promissory note with an outstanding balance of $3,213 at December 31, 2021, the Company issued 6,235,512 SVS to Healthy Pharms Inc.
On January 28, 2022, pursuant to an agreement and plan of merger whereby New England Cannabis Corporation, Inc., a Massachusetts corporation (“NECC”) became a wholly owned subsidiary of the Company, the Company issued 28,571,428 SVS, with a deemed value of $1.05 per share, or a total estimated valuation of $30,000,000 to Mr. Kenneth V. Stevens, the sole owner of all of the issued and outstanding capital stock of NECC.
On April 25, 2022, pursuant to an agreement and plan of merger whereby Island Global Holdings, Inc., a California corporation (“Island”) became a wholly owned subsidiary of the Company, the Company issued an aggregate of: 8,783,716 SVS and warrants to purchase 2,999,975 SVS at a price of $1.00 per SVS to certain shareholders and debtholders of Island.
The foregoing transactions did not involve any underwriters, any underwriting discounts or commissions, or any public offering. We believe the offers, sales, and issuances of the above securities were exempt from registration under the Exchange Act (including Regulation D promulgated thereunder) by virtue of Section 4(a)(2) of the Securities Act, because the issuance of securities to the recipients did not involve a public offering. The recipients of the securities in each of these transactions represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were placed upon the stock certificates issued in these transactions. All recipients had adequate access, through their relationships with us or otherwise, to information about us. The issuances of these securities were made without any general solicitation or advertising.
40
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not Applicable.
Item 5. Other Information
There is no other information required to be disclosed under this item which was not previously disclosed.
41
Item 6. Exhibits
Exhibit Number |
Exhibit Description |
Form |
Filing Date |
Exhibit Number |
Filed Herewith |
|||||||||||||
31.1 | Certification of the Chief Executive Officer (Principal Executive Officer) pursuant to Rule 13a-14(a) of the Securities Exchange Act | x | ||||||||||||||||
31.2 | Certification of the Chief Financial Officer (Principal Financial Officer) pursuant to Rule 13a-14(a) of the Securities Exchange Act | x | ||||||||||||||||
32.1 | Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Rule 13a-14(b) Under the Securities Exchange Act of 1934 and Section 1350 of Chapter 60 of Title 18 of the United States Code * | x | ||||||||||||||||
101.INS | Inline XBRL Instance Document | |||||||||||||||||
101.SCH | Inline XBRL Taxonomy Extension Schema Document | |||||||||||||||||
101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |||||||||||||||||
101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | |||||||||||||||||
101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | |||||||||||||||||
101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |||||||||||||||||
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
+ | Indicates management contract or compensatory plan. |
* | This certification is being furnished solely to accompany this Quarterly Report pursuant to 18 U.S.C. Section 1350, and it is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934 and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. |
42
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
4FRONT VENTURES CORP. | ||||
Date: May 23, 2022 | By: | /s/ Leo Gontmakher | ||
Leo Gontmakher | ||||
Chief Executive Officer and Director | ||||
(Principal Executive Officer) | ||||
Date: May 23, 2022 | By: | /s/ Andrew Thut | ||
Andrew Thut | ||||
Chief Investment Officer and | ||||
Interim Chief Financial Officer | ||||
(Principal Financial Officer) |
43